

Republic of Yemen
Ministry of Higher Education and Scientific
Research
21st Medical University
Faculty of Clinical Pharmacy



Cardiohepatic Syndrome among Heart Failure Patients in Yemen

A graduation research project submitted in partial fulfillment of requirements of
for obtaining bachelor degree in pharmacy

Submitted by Students:

Ahmed Ebrahim Ali Mohammed Alkhuli	Ghadah Adel Mutahar Badi
Aseel Abdul-Jabbar Saleh Muthanna	Asala Abdulhalim Gasem Ali khawez
Rishan	Noor Ali salam Alazazi
Ibrahim Abdullah Ahmed Baker	Sara Abdulaziz Mohammed Alboukair
Osama Hassan Mohammed Al Quaish	Abeer Mohammed Qasem Ali Mahdi
Aseel Abdulhalim Gasem Ali. khawez	Lamia Mahmoud Modhish
Haitham Hamis Abdullah Qasim	
Tariq Ali Mohammed Al Sayaghi	

Under the Supervision of:

Dr. Shawqi Hussein Nagi Al-Awdi

Assistant Professor of Pharmacology and Clinical Pharmacy
Faculty of Medicine – Tamar University

Dr. Mokhtar Abdul Hafiz Al-Ghorafi

Associate Professor of Medicinal and Organic Chemistry
Faculty of Pharmacy – Sana'a University

2021 – 2022

وَقُلْ لِّعَلَّامِينَ

فَسِيرِ اللَّهِ عَلَيْكُمْ وَرُسُلِهِا وَالْمُؤْمِنُونَ

صَدَقَ اللَّهُ الْعَظِيمُ، (التوبة آية ١٠٥)

Dedication

We dedicate our research to our families specially our beloved parents, who they educate us and enabled us to reach at this level. Thank you for all the things you have done for us as we have grown up.

Moreover, we want to dedicate this research to our respected supervisors **Ass prof Dr. Shawqi Hussein Nagi Al-Awdi** and **Ass prof Dr. Mokhtar Al-Ghorafi**.

They were supported us on every step of our research durations. Without them, it could might never possible to complete this research project.

Our supervisors made us able to face different challenges and win those challenges. In addition, we wish to dedicate this research to our friends, nurses, pharmacists, doctors and the rest of the health practitioner.

Acknowledgement

First and foremost, We would like to thank god Almighty for giving us the strength, knowledge, ability and opportunity to undertake this research study and complete it satisfactorily.

What a beautiful life among people who embrace science and love life for us, we would like to thank our supervisors, **Ass Prof. Dr Shawqi Hussein Nagi Al-Awdi, and Ass Prof. Dr Mokhtar Abdul Hafiz Al-Ghorafi** all respect and appreciation and wish you the health and wellness.

For the patient guidance, encouragements and advices. He has provided throughout our time as their students. We have been extremely lucky to have supervisors who cared so much about our work, thanks and appreciation, and the Lord of the Throne protects you.

We also extend our sincere gratitude to those sincere people, who have spared no effort in helping us in the field of scientific research especially the **Ass Prof. Mujahed Masaar head of 21 sep University, and Ass prof Dr. Abdul Malik Abu-dunia dean of the faculty of clinical pharmacy in 21 sep University**, Also special thanks for the all doctors and employees in our university.

who have the most prominent role in our rehabilitation and that through the selection of distinguished scientific cadres and through which we have reached this stage of scientific bachelor's degree.

Contents

Subject	Page
Contents.....	i
List of tables.....	iii
List of figures.....	iv
List of abbreviations.....	ii
Abstract.....	vii
Introduction and aim of the work.....	1
Review of Literature.....	5
Subjects and Methods	24
Results.....	29
Discussion.....	40
Summary and conclusions.....	43
References.....	46
Arabic Summary	---

List of Tables

Title	Page
1. Gender distribution of cardiohepatic syndrome patients	35
2. Age distribution of cardiohepatic syndrome patients	36
3. Health facilities distribution of cardiohepatic syndrome patients	37
4. Clinical signs in patients with cardiohepatic syndrome	38
5. Blood pressure and pulse findings in cardiohepatic patients	39
6. Laboratory tests findings in cardiohepatic patients	41
7. Classification of heart failure according to ejection fraction	42
8.	
9.	
10.	
11.	

List of Figures

Title	Page
1. Gender distribution of cardiohepatic syndrome patients	35
2. Age distribution of cardiohepatic syndrome patients	36
3. Health facilities distribution of cardiohepatic syndrome patients	37
4. Clinical signs in patients with cardiohepatic syndrome	38
5. Blood pressure and pulse findings in cardiohepatic patients	39
6. Classification of heart failure according to ejection fraction	41
7.	
8.	
9.	
10.	
11.	

List of abbreviations

2-AG	Anandamide and 2-Arachidonoylglycerol
ACE	Angiotensin-Converting Enzyme
AEA	Arachidonylethanolamide
ALP	Alkaline Phosphatase
ALT	Alanine Aminotransferase
ANF	Atrial Natriuretic Factor
ARBs	Angiotensin Receptor Blockers
AST	Aspartate AminoTransferase
ATP	Adenosine Triphosphate
BMI	Body Mass Index
BNP	B-type Natriuretic Peptide
CB-1	Cannabinoid Receptor Type 1
CBRs	Cannabinoid Receptors
CCM	Cirrhotic Cardiomyopathy
CCTA	Coronary Computed Tomography Angiography
CFR	Coronary Flow Reserve
CRP	C-Reactive Protein
cTnC	Troponin C
cTnI	Troponin I
FetA	Fetuin-A
FGF21	Fibroblast Growth Factor 21
GGT	Gamma-GlutamylTransferase

Il-1 β	Interleukin 1 beta
iNOs	Nitric Oxide Synthetase
INR	International Normalized Ratio
ITVR	Isovolumetric Relaxation Time
LDH	Lactate Dehydrogenase
LDL-C	Low-Density lipoprotein Cholesterol
LT	Liver Transplantation
LVAD	Left Ventricular Assistive Device Support
MED13	Mediator Complex Subunit 13
miR-208a	MicroRNA-208a
mtDNA	Mitochondrial DNA
Myh6	Myosin Heavy Chain 6
NAFL	NonAlcoholic Fatty Liver
NAFLD	NonAlcoholic Fatty Liver Disease
NASH	NonAlcoholic SteatoHepatitis
NFS	NAFLD Fibrosis Score
NF- κ B	Nuclear Factor κ B
NLRP3	NOD-like Receptor Protein 3
NO	Nitric Oxide
PAI-1	Plasminogen Inhibitor Activator 1
PKA	Protein Kinase A
ROS	Reactive Oxygen Species
TGF- β 1	Transforming Growth Factor- β 1
TTC	TakoTsubo Cardiomyopathy
VLDL-C	Very Low-Density Lipoprotein Cholesterol

Abstract

Cardiohepatic Syndrome among Heart Failure Patients in Yemen

Aims of the study: The present study was aimed to investigate the clinical patterns of cardiohepatic syndrome among patients with heart failure attending several private and public hospitals in Sana'a city, Yemen.

Methods: The study was a clinical cross-sectional study performed on patients with heart failure admitted to the medical departments at several private and public hospitals in Sana'a city between July 1, 2021 and December 31, 2021.

Results: A total of 162 diagnosed cases of cardiohepatic syndrome were studied. Male patients were 117 (72.2%) and female patients were 45 (27.8%). The age of patients with cardiohepatic syndrome ranged between 0.5 and 81 years. The results of the present study showed that most patients with cardiohepatic syndrome aged between 41 and 70 years (66.1%). Most cardiohepatic syndrome patients were admitted to Lebanon hospital (75.3%) followed by Althawra hospital (10.5%). Patients with cardiohepatic syndrome most frequently presented with edema (56.2%), pallor (40.7%), and cyanosis (25.3%). Other less frequent signs were icterus (8.6%) and clubbing (8%). The average pulse rates in cardiohepatic syndrome patients was 94 ppm (maximum 142 and 37 minimum), the average systolic blood pressure was 118mmHg (maximum 200 and 60 minimum), and the average diastolic blood pressure was 75 mmHg (maximum 120 and minimum 40). The laboratory investigations that were performed for the patients to assess liver function included Total bilirubin, Direct bilirubin, Indirect bilirubin, AST, ALT, ALP, Total protein, Albumin, Prothrombin time, and Activated partial thromboplastin time. Additionally, routine complete blood count and kidney function tests were performed. Large proportion of patients (55.7%) had heart failure with preserved ejection fraction (HFpEF) while 28.2% of the patients had heart failure with reduced ejection fraction (HFrEF). Minority (9.9%) of the patients had heart failure with mid-range ejection fraction (HFmrEF) and 6.1% of the patients had normal ejection fraction.

Conclusions: Cardiohepatic syndrome presents with a full-range of signs,

symptoms, and lab test deviations, and is more prevalent in male, middle-aged heart failure patients. Cardiohepatic syndrome is also more likely in patients with reduced ejection fraction.

Chapter: 1

Introduction and Aim of the study

1.1 Introduction

Heart failure (HF) is a major public health problem, with frequent hospitalizations, impaired quality of life, and shortened life expectancy [1]. As HF advances, it is often characterized by an increasing inability to meet the metabolic requirements of end organs or skeletal muscle. While much attention has been directed toward the intersection of HF and renal function, the impact of HF on hepatic function has been poorly described.

Similar to the now widely described “cardiorenal” syndromes, more attention is needed in describing “cardiohepatic” interactions. Over the last several years, a number of studies have described poor outcomes associated with the development of cardiorenal syndromes, as well as potential solutions to mitigate further renal injury while treating HF [2]. In contrast, much less is known about impaired liver function in patients with HF. Furthermore, HF patients may present with liver-related symptoms including abdominal distention, intermittent right upper quadrant discomfort, nausea, early satiety, or anorexia. The presence of these symptoms may direct a primary gastrointestinal evaluation rather than consideration of primary cardiac pathology, thereby creating a delay in the initiation of

life-prolonging interventions.

Abnormalities in liver function tests (LFTs) are not an uncommon finding in patients with HF. These abnormalities are a result of impaired perfusion or elevated right-sided cardiac pressures, or are secondary to drug toxicity. Attempts at describing the features of chronic liver damage secondary to HF have been ongoing since the early 20th century [3,4]. Nevertheless, neither the pathophysiologic basis underlying these findings nor the clinical impact of impaired liver function on HF outcomes have been clearly delineated.

1.2 Aims of the study:

General objectives:

The present study was aimed to investigate the clinical patterns of cardiohepatic syndrome among patients with heart failure attending several private and public hospitals in Sana'a city, Yemen.

Specific objectives:

1. To study prevalence of liver function abnormalities in heart failure patients using liver function tests.
2. To correlate the liver function tests abnormalities with Clinical, Biochemical and Radiological severity of heart failure patients.
3. To highlight how chronic liver diseases may impair cardiac

performance and induce electrophysiological abnormalities in the absence of other cardiac diseases.

Chapter: 2

Review of Literature

2. Literature Review

1. Introduction:

Heart failure (HF) is a major public health problem leading to frequent hospitalizations, impaired quality of life, and shortened life expectancy. Heart failure leads to a chronic inability to meet metabolic requirements of end organs or skeletal muscle. For many years, a mutual interaction between the heart and the liver has been established. Avicenna first pointed out the interactive effects between these two organs in his famous book titled as "Canon" (The Law). This interaction was described as dominance of the "heart warmth" over "liver coldness and wetness" and the dominance of "liver dryness" over "heart wetness". According to traditional medicine, each organ is composed of four temperaments where the "wetness" and "dryness" are considered as a spectrum of "tissue moistures", while "warmth" and "coldness" may be regarded as the basic metabolism of the organ. In normal condition, the heart's temperament is "warm" and "dry" and the liver temperament is "warm" and "wet". According to Avicenna, the presence of imbalance between the temperaments of human body describes the state of illness or organ disorder [1]. Both heart and liver diseases are

regarded as a serious burden on health system and a leading cause of deterioration of quality of life and shortened life expectancy.

2. The heart as a Cause of Liver Disease

2.1. Congestive Hepatopathy

Congestive hepatopathy or chronic passive hepatic congestion refers to the congestion of liver parenchyma induced by impaired hepatic venous outflow secondary to a right-sided cardiac failure (Figure 1a).




Figure 1: The suggested mechanisms underlying the cardiohepatic interactions in the setting of main heart and liver dysfunctions. (a) Congestive hepatopathy is most commonly observed in valvular heart diseases, cardiomyopathy, left heart failure, and constrictive pericardial disease. (b) An acute decrease in cardiac output may result in cardiogenic ischemic hepatitis. (c) In liver cirrhosis, the combination of portal hypertension, impaired cardiac beta-adrenergic responsiveness, and cardiac extracellular matrix remodeling is involved in the development of cirrhotic cardiomyopathy. (d) Stress cardiomyopathy is an acute

heart failure syndrome that may appear in the perioperative period after liver transplantation. (e) Insulin resistance, subclinical inflammation, oxidative stress, ectopic fat deposition, atherosclerosis, and endothelial dysfunction are considered the main mechanisms linking NAFLD with cardiac complications

2.1.1. Pathophysiology and Presentation

The underlying pathophysiological mechanisms include increased hepatic vein pressures, decreased hepatic blood flow, and decreased arterial oxygen saturation [2,3]. Main cardiac conditions associated with congestive hepatopathy include valvular diseases (tricuspid regurgitation and mitral stenosis), cardiomyopathy, left heart failure, and constrictive pericardial disease [4,5]. A growing population of patients at high risk for the development of chronic passive hepatic congestion is represented by adults with single ventricle congenital heart disease who have undergone surgical palliation with the Fontan's procedure. This surgical procedure consists of connecting a single working heart ventricle to the systemic circulation while allowing passive venous return to the pulmonary arteries. Over time, central venous pressure increases and cardiac output decreases resulting in severe hepatic congestion [6].

Congestive hepatopathy is usually subclinical. When symptomatic, patients may present with early satiety, malaise, mild jaundice, or

intermittent right upper quadrant pain secondary to dilatation of the liver capsule. Physical examination is typically dominated by signs of cardiac failure including jugular vein distension, hepatojugular reflux, and peripheral edema. Spider angiomas, splenomegaly, and varices are rarely present [5,7]. The presence of esophageal varices indicates an elevated transhepatic pressure gradient due to progression toward liver fibrosis [8]. In addition, presence of pulsatile liver can be noticed in the setting of tricuspid valve regurgitation. The loss of this pulsatility over time suggests the progression from congestive hepatopathy to secondary liver cirrhosis known as cardiac cirrhosis, a term grouping all the hepatic disorders that occur secondary to hepatic congestion due to cardiac dysfunction, mainly the right heart [9].

2.1.2. Biochemical Pattern

Primary laboratory finding in congestive hepatopathy is represented by mild hyperbilirubinemia, with a predominantly unconjugated fraction [3]. Elevations in markers of cholestasis (alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT)) are also characteristic of congestive hepatopathy and have been shown to correlate with right atrial and central venous pressures [10,11].

Mild hypoalbuminemia and ascites may be present in patients with congestive hepatopathy. In these patients, the state of inadequate nutrition and hemodilution due to heart failure contributes substantially to the aggravation of hypoalbuminemia [12].

2.1.3. Histopathology

Morphologically, congestive hepatopathy is associated with characteristic changes within the liver parenchyma [3,13,14]. Elevated hepatic venous pressure is transmitted to lobular hepatic vessels inducing an enlargement of sinusoidal fenestrae [5]. The dilatation of hepatic sinusoids is correlated with degree of venous pressure and results in the exudation of red blood cells and protein rich-fluid into the perisinusoidal space of Disse [5]. Prolonged perivenular congestion induces the so-called cardiac liver cirrhosis characterized by local steatotic changes, atrophy, and/or necrosis within the centrilobular hepatic parenchyma (zone 3). Over time, this may progress in deposition of sinusoidal collage to form broad fibrous septa that extend between adjacent central hepatic veins [15]. This pattern of bridging fibrosis produces a typical histologic aspect referred as “reverse lobulation” [16]. The degree of fibrosis varies within the spatial regions of the livers. This heterogeneity is likely

related to the fibrogenic effects of focal thrombotic events within the hepatic venules and sinusoids due to the chronic vascular congestion. The gross pathological appearance of a liver affected by chronic venous congestion has been described as “nutmeg liver”. This speckled appearance is due to the extravasation of red blood cells from the centrilobular sinusoids, which leads to reddened areas within the hepatic parenchyma [17].

2.1.4. Management

Treatment of congestive hepatopathy consists mainly of treating the underlying cardiac disease and improvement of cardiac output. Diuretics represent the main stay of pharmacological therapy. Unless contraindicated, angiotensin-converting enzyme (ACE) inhibitors and beta blockers are indicated in symptomatic congestive heart failure. A surgical approach may be indicated in the case of constrictive pericarditis, severe valvular heart disease, and ischemic cardiomyopathy [9,18]. For patients with end-stage heart failure, temporary left ventricular assistive device support (LVADs) or cardiac transplantation may help to improve congestive hepatopathy [19,20].

2.2. Cardiogenic Ischemic Hepatitis

Cardiogenic ischemic hepatitis, known also as acute cardiogenic liver

injury, is a clinical and histological syndrome characterized by a rapid and transient rise in serum transaminase levels due to acute fall in cardiac output leading to the reduction of hepatic blood flow [21] (Figure 1b).

2.2.1. Pathophysiology and Presentation

Cardiogenic ischemic hepatitis has been estimated to emerge in 20–30% of patients with acute heart failure [22]. The pathophysiological mechanisms involved in this acute liver damage are mainly related to changes of hepatic blood flow. In physiological conditions, hepatic blood flow accounts for about 20% of the cardiac output, delivered to the liver via the arterial hepatic system and the portal vein. Reduced portal venous flow, due to a decrease in cardiac blood flow, leads to a rise in adenosine levels which is synthesized by liver cells and Kupffer cells. The increased adenosine levels induce an apparently protective hepatic artery dilatation via an autoregulatory mechanism known as “hepatic arterial buffer response” [23]. Nevertheless, when hypotension is persistent, visceral flow is critically reduced and severe hypoxemia develops, leading to hepatocellular hypoxia and necrosis after overwhelming the compensatory mechanisms [24].

An acute cardiogenic liver injury is usually related to an acute coronary event, cardiac arrhythmia, or transient severe hypotension [25]. Findings from a retrospective study demonstrated that acute decline in hepatic perfusion during cardiogenic shock is not the sole incident underlying the development of acute liver injury. The analysis proposed that hepatic venous congestion due to right-sided heart failure predisposes to acute hepatic injury induced by hypotensive event [21].

In another report of patients with clinical and biochemical evidence of acute liver injury admitted to the coronary intensive care unit, the presence of acute liver injury has been shown to be associated with a decrease in hepatic blood flow and passive hepatic venous congestion [24]. Additionally, Birrer et al. showed that systemic vascular resistance and mean pulmonary capillary wedge pressure were elevated in patients with acute hypoxic liver injury [26]. Taken together, these findings suggest that the combination of hepatic venous congestion coupled with acute cardiac event is required for the development of acute cardiogenic liver injury.

Acute cardiogenic hepatitis is usually asymptomatic. However, clinical signs may appear after a latency period of 2–24 h. Most

commonly, patients exhibit symptoms resembling acute viral hepatitis such as weakness, apathy, and, in a minority of cases, mental confusion, flapping tremor, oliguria, jaundice, and hepatic coma [25,27].

2.2.2. Biochemical Pattern

The diagnostic approach of cardiogenic ischemic hepatitis is usually based on clinical presentation and laboratory finding. Non-invasive imaging as abdominal ultrasound can be supportive by showing signs liver congestion as dilation of the suprahepatic veins and inferior vena cava [28]. Pulmonary hypertension and impaired systolic left ventricular function are frequently observed by echocardiography. Other imaging techniques such as magnetic resonance or computed tomography or imaging, may be implied to exclude other causes of liver injury [28].

The typical pattern in laboratory tests consists of rapid, transient rises in serum aminotransferase (aspartate [AST] and alanine aminotransferase [ALT]) and lactate dehydrogenase levels (LDH) with peak levels reaching between 10 and 20 times the upper limit of normal [3,29].

The ratio of serum ALT to lactate LDH less than 1.5 early in the

course of liver injury is characteristic of cardiogenic injury [30]. After correction of the underlying process, these liver enzymes drop gradually and reach normal values within 7–10 days [3]. Other non-specific laboratory abnormalities include an elevation in total serum bilirubin levels. In addition, International Normalized Ratio (INR) can be prolonged due to deficiency of liver coagulation factors [31].

2.2.3. Histopathology

The main histologic feature of acute cardiogenic ischemic hepatitis is characterized by hepatic necrosis around the central hepatic veins (zone 3), a condition known as centrilobular necrosis. This zone has the poorest oxygen delivery, and will be most affected during a low hepatic blood flow [3]. In cases of prolonged circulatory collapse, necrotic changes may extend to midzonal periportal segments (zone 2) [3,32].

2.2.4. Management

The management of cardiogenic ischemic hepatitis focuses on identifying and removing the precipitating cause. This may include medications with hypotensive or negative inotropic effects and other medications that likely may induce impairment of renal function.

When needed, administration of oxygen and positive inotropic agents

may help to restore an adequate organ perfusion [33].

3. The Liver as a Cause of Heart Disease

3.1. Cirrhotic Cardiomyopathy

Cirrhotic cardiomyopathy (CCM) was first described in the late 1960s, although for many years, it was mistakenly presumed to result from a latent alcoholic cardiomyopathy [34]. CCM represents a clinical entity in patients with cirrhosis characterized by a combination of impaired myocardial contractile responsiveness to stress, diastolic dysfunction along with electrophysiological disturbances, in the absence of other known cardiac disease [35,36]. Although the diagnosis of CCM is usually missed or delayed, it was estimated that this condition can be present in up to 50% of patients with cirrhosis (Figure 1c) [37].

3.1.1. Pathophysiology and Presentation

Hyperdynamic Circulation

In hepatic cirrhosis, portal hypertension results in splanchnic arterial vasodilation due to the release of potential liver-derived vasodilators factors such as carbon monoxide, nitric oxide, and prostacycline [38,39]. This leads to reduced systemic vascular resistance, low arterial blood pressure, increased splanchnic blood redistribution, and

central hypovolemia [40,41]. The state of central hypovolemia is also enhanced through the portosystemic shunting and bacterial translocation. Taken together, these processes induce an activation of sympathetic nervous system with consequent hyperdynamic circulation due to an increase of heart rate and cardiac output [42].

Systolic Dysfunction

Patients with liver cirrhosis present an impaired ventricular ejection of fraction under physical stress compared with non-cirrhotic subjects. This is mainly related to inadequate heart rate response and decreased myocardial contractility under exercise [43,44].

Alterations in β -adrenergic receptor function at the membrane of cardiac muscle cells have been shown to be involved in the myocardial hyporesponsiveness of cirrhotic patients. It is well accepted that the long-term exposure of cardiomyocytes to high levels of noradrenalin usually present in cirrhosis due to enhanced sympathetic tone results in internalization, sequestration, and down regulation of β -adrenergic receptors on plasma membrane [45,46].

Experimental findings from animal models suggested that nitric oxide (NO) could play a negative inotropic effect in heart of cirrhotic rats [47]. The activation of NO-pathway in heart tissue of cirrhotic rats has

been shown to be at least in part related to the stimulation of inducible NO synthetase (iNOs) through the elevated levels of proinflammatory cytokines such as interleukin 1 beta (IL-1 β) and tumor necrosis factor alpha (TNF- α) [48]. In this regard, the endocannabinoid system has been shown to contribute to the decreased contractility of cardiomyocyte in experimental liver cirrhosis [49]. The increased endotoxemia which may occur in liver cirrhosis has been shown to enhance the production of macrophage-, lymphocyte- and platelet-derived endocannabinoids [50].

In this context, arachidonylethanolamide (AEA) or anandamide and 2-arachidonoylglycerol (2-AG) are the most widely studied endocannabinoids, exerting their effects via G protein-coupled cannabinoid receptors (CBRs). The activation of cannabinoid receptor type 1 (CB-1) has been shown to decrease the contractile response to β -adrenergic agonists. This cardiac adrenergic responsiveness was restored by blockage of CB-1 receptor [51]. In addition, elevated cardiac levels of anandamide have been shown to mediate at least in part the inhibitory effects of TNF- α on cardiac contractility [52].

Diastolic Dysfunction

Abnormalities of diastolic dysfunction are considered an early

manifestation of CCM, and frequently precede the systolic dysfunction. Left ventricular diastolic dysfunction is characterized by a decrease in the rate and degree of left ventricular relaxation, together with presence elevated end-diastolic filling pressures [53]. Unlike contractile systolic failure, which usually appears under stress conditions, echocardiographic findings of diastolic dysfunction can also manifest at rest [54]. However, its underlying mechanisms remain to be fully elucidated. In a rat model of liver cirrhosis, alterations in titin protein modulation have been shown to be an important determinant of diastolic stiffness in CCM. Titin is a giant multi-functional sarcomeric filament that provides passive stiffness to cardiomyocytes and thus responsible for the elasticity of the relaxed striated muscle [55]. Moreover, it was hypothesized that abnormalities in the cardiac β -adrenergic signaling pathway induce a decrease in protein kinase A (PKA) levels that may ultimately impair phosphorylation of titin and subsequently increase passive tension of left ventricle. Additionally, a reduced level of PKA induces a decrease in PKA-dependent cardiac troponin I (cTnI) phosphorylation, which leads to decreased dissociation of calcium from cardiac troponin C (cTnC) and thus may alter rate of cardiac muscle relaxation [56].

Liver cirrhosis was associated with changes in expression of collagen isoforms in ventricular heart tissue has been shown to be involved to correlate with diastolic dysfunction in cirrhosis. Ventricular cardiac tissue derived from cirrhotic rats showed an increased collagen type 1 content compared with sham animals, which subsequently contributes significantly to diastolic dysfunction by increasing the passive cardiac stiffness [55].

Electrophysiological Modifications

A prolonged QT interval represents a common electrocardiographic finding in patients with cirrhosis and served as predictor of the increased risk of ventricular arrhythmia and/or sudden death [57]. QT prolongation has been attributed to the downregulation of β -adrenergic receptors after chronic exposure to noradrenalin [58]. In addition, elevated bile salts as well as uric acid plasma level have been shown to predispose to prolonged QT intervals in cirrhotic patients [59].

Chronotropic incompetence is another consistent finding in CCM, and refers to the inability of the heart to increase adequately its rate to match the metabolic demands. Cardiovascular autonomic dysfunction has been suggested to play a role in enhancing

chronotropic incompetence in patients with CCM [60].

3.1.2. Diagnostic Approach

Considering the subclinical picture of CCM in the majority of patients, the diagnostic approach involves a combination of laboratory, clinical, electrocardiographic, and imaging evaluations. Electrocardiographic assessments may be helpful to identify cirrhotic patients with prolongations of QT interval and arrhythmias. Echocardiographic evaluation of the left ventricular systolic function usually shows a reduction of ventricular ejection of fraction at rest or under stress in response to catecholamine stimulation in the case of subtle systolic dysfunction. Diastolic impairment in CCM manifests mainly by reduced early (E) ventricular filling capacity and increased atrial (A) filling ($E/A < 1.0$), in addition to prolongation of deceleration time (> 200 ms) and isovolumetric relaxation time (ITVR > 80 ms) [61].

Biomarkers for cardiac dysfunction (cTnI, B-type natriuretic peptide [BNP], and [pro-BNP]) might be elevated in early stages of CCM and usually reflect the severity of liver disease [62].

3.1.3. Management

CCM complicates several therapeutic approaches used in cirrhosis and heart failure. Although beta blockers are contraindicated in

decompensated cirrhosis with ascites, these drugs have been shown to normalize the prolonged QT interval and might reduce the hyperdynamic load [63]. ACE inhibitors and angiotensin receptor blockers (ARBs) are contraindicated in presence of ascites because of the risk of hypotension and hepatic-renal syndrome [63]. LT may be an effective treatment for end-stage liver disease associated with CCM since it has been shown to reverse cardiac dysfunction and electrophysiological abnormalities [63]. However, many cardiac complications have been reported in patients with CCM undergoing LT [64].

3.2. Liver Transplantation

Cardiovascular events and mainly heart failure represent a primary source of morbidity and mortality following LT. Heart failure may have an early-onset (within 30 days after transplantation) or in other cases may occur late (>30 days). In the postoperative period, heart failure may reach an overall incidence of 3.3% and may be associated with a mortality risk of 45% [65] (Figure 1d).

Stress-Induced Cardiomyopathy

Clinical Presentation

The cardiovascular stress due to surgery is considered a main

contributor of early heart failure in liver transplanted patients. Takotsubo cardiomyopathy (TTC) or stress-induced cardiomyopathy represents a main cause of acute heart failure in the absence of coronary artery disease [66]. TTC's clinical pattern is distinctive since it is characterized by a transient hypo- or dyskinesia of the apical, lateral, and posterior wall of left ventricle and a preservation of the basal cardiac segments [67,68]. Even though the clinical presentation is often dramatic and accompanied by cardiogenic shock and lethal arrhythmias, the recovery is usually rapid and complete [69,70]. Even though TTC occurs in the absence of angiographic evidence of coronary artery disease, it is often difficult to differentiate this entity from an ischemic event related to coronary thrombosis.

Pathophysiology

Several pathophysiological mechanisms have been suggested to be involved in TTC. The exposure of myocardium to large concentrations of circulating catecholamines during LT makes the heart susceptible to adverse events including multivessel epicardial vasospasm [71]. In addition, the altered adrenergic and Gs protein signaling pathways that are commonly found in heart tissue of cirrhotic patients have been suggested to contribute in TTC physiology [72].

Intraoperative triggers for TTC during liver transplantation surgery include cardiovascular stress, such uncontrolled bleeding, massive transfusions, and administration of high rates of vasoactive agents [73].

Predictors and Diagnostic Approach

Stress-induced cardiomyopathy is still an underestimated cause of acute heart failure in liver transplanted patients. Beside the exclusion of coronary disease, the diagnostic approach should involve the combination of clinical aspects to electrocardiographic and echocardiographic findings. Multiple studies have evaluated the risk factors for late cardiac events following LT. The severity of liver disease as quantified by Model of End Stage Liver Disease (MELD) score has been shown to be associated with adverse cardiac events following LT [74]. This was attributed to presence CCM and its components including diastolic dysfunction and prolonged QT interval [75,76].

In addition to older age and male sex, several components of the metabolic syndrome factors including hypertension, hyperglycemia, dyslipidemia, and visceral obesity have been shown to be predictive for heart failure following LT [77,78]. In this context, elevated pre-

transplantation blood urea nitrogen plasma levels and hemodialysis increase the risk of postoperative heart failure [79]. Similarly, pulmonary hypertension and presence of history for cardiac disease including arrhythmia and coronary artery disease have been shown to predict post-transplantation cardiac complications [74,77]. Currently, LT candidates undergo a preoperative systemic assessment to improve the post-transplantation outcome. This includes a full history and examination, 12-lead ECG, and two-dimensional echocardiography to detect structural and functional heart abnormalities and estimate pulmonary artery pressure. Based on the findings of the initial screening test, liver transplant recipients who are at high-risk for coronary artery disease undergo further invasive investigations such as dobutamine stress echocardiography, coronary angiography, and coronary computed tomography angiography (CCTA) [80].

Management

Hemodynamically stable patients are often treated with diuretics, ACE inhibitors, and beta blockers. Treatment with calcium channel blockers and fluid resuscitation is usually indicated for patients with severe left ventricular outflow tract obstruction and hemodynamic

compromise. Inotropic agents can be administered only in absence of moderate or severe left ventricular outflow tract obstruction. In presence of TTC with thromboembolism, anticoagulation should be continued for at least three months [81].

3.3. Nonalcoholic Fatty Liver Disease

3.3.1. Definition and Prevalence

NAFLD encompasses a pathological condition characterized by ectopic deposition of adipose tissue in the liver, in the absence of secondary causes for hepatic fat accumulation, such as excessive alcohol intake, steatogenic drugs, and hereditary disorders [82]. This terminology covers a wide spectrum that ranges from simple steatosis or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) and cirrhosis. Hepatic steatosis is considered a benign and reversible stage characterized by excessive fat infiltration involving more than 5% of the liver parenchyma, with no evidence of hepatocyte injury. NASH is characterized by steatosis with hepatocellular inflammation that may further progress in liver fibrosis, cirrhosis, and hepatocellular carcinoma [83].

NAFLD is the most common chronic liver disease worldwide with a prevalence of about 20–30% in the general population and it is

estimated to be 50–90% in people with obesity and type 2 diabetes mellitus. Today, the global prevalence of NAFLD mirrors the steady increase in obesity rate and correlates with its degree. Hepatic steatosis is found in 65% of subjects with grade I–II obesity (BodyMass Index [BMI] = 30–39.9 kg/m²) and in 85% of patients with morbid obesity (BMI = 40–59 kg/m²) [84]. There is large growing evidence suggesting that NAFLD contributes potentially to the increased risk for cardiovascular-related morbidity and mortality [85,86]. According to the Framingham scoring approach, the mean of respective cardiovascular risks in subjects with and without NAFLD was estimated as 16.0% and 12.7% in men and 6.7% and 4.6% in women, respectively [87].

3.3.2. Cardiac Disorders in NAFLD

The most common cardiac complications associated with NAFLD include coronary artery disease, and structural myocardial alterations in addition to cardiac arrhythmias. An increasing number of studies have addressed a link between coronary heart disease and NAFLD independently of traditional cardiovascular risk factors [88]. Patients with NAFLD showed a higher prevalence of calcified and non-calcified coronary plaques compared to healthy individuals independently of

the presence of the metabolic syndrome components [89].

Moreover, the coronary microvascular and endothelial function assessed by the measurement of coronary flow reserve (CFR) has been shown to be impaired in patients with NAFLD compared with healthy subjects [90].

Moreover, subjects with NAFLD have been shown to have common features of left ventricular diastolic dysfunction, which represents a key contributor to the development of heart failure [91]. Similarly, a higher prevalence of left ventricular mass index compared to controls has been observed [92]. Furthermore, NAFLD has been associated with morphological and valvular heart abnormalities. Several studies showed that hepatic steatosis is associated with aortic-valve sclerosis and mitral annular calcification, both known to enhance the risk of cardiac arrhythmias and heart failure [93,94].

Cardiac rhythm disturbances are also linked to NAFLD, probably due to an induction of cardiac autonomic dysfunction. Several arrhythmias are found in association with NAFLD such as atrial fibrillation, QT prolongation, and ventricular arrhythmias, which can predispose these patients to sudden cardiac death [95].

3.3.3. Mechanisms Linking Cardiac Disorders to NAFLD

The precise mechanisms linking NAFLD with cardiac complications are poorly understood. However, several pathophysiological mechanisms have been postulated to be involved such as insulin resistance, visceral adiposity, subclinical inflammation, dyslipidemia, and oxidative stress ([Figure 1e](#)) [96].

NAFLD patients tend to present whole-body as well as hepatic insulin resistance, inducing disturbances in the transport of free fatty acids, thus leading to visceral and ectopic fat accumulation. Due to the increased lipogenesis, the lipid profile in these subjects consists in increased levels of triglyceride, low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C), which are consequently linked to increased cardiovascular risks [97,98].

NAFLD is considered a chronic subclinical inflammatory condition through secreting proinflammatory cytokines and chemokines by both hepatocytes and by non-parenchymal cells such as stellate cells and Kupffer cells [99]. Several inflammatory markers as well as serum levels of IL-6, IL-1, TNF- α , and C-reactive protein (CRP) have been demonstrated to be related to cardiovascular events in NAFLD [100].

In addition to the role of abdominal obesity, which usually occurs in NAFLD, ectopic fat accumulation in other districts (i.e. perivascular, pericardial, and epicardial) leads to adipocytes dysfunction with consequent imbalance of pro- and anti-inflammatory cytokines originating from adipose tissue termed adipokines [101,102]. In this context, an increase in proinflammatory cytokines such as leptin and a decrease of cardioprotective one such as adiponectin have been reported in NAFLD [102]. This induces a persistent deterioration of the inflammatory and insulin resistant states that consequently lead to the worsening of cardiometabolic outcomes [101].

Oxidative stress appears to play a key role in promoting the progression from simple steatosis to NASH and increasing the cardiometabolic risk in NAFLD patients [103]. It arises as a consequence of an imbalance between excessive generation of reactive oxygen species (resulting from accelerated FFA influx and de novo lipid synthesis) and antioxidant defenses leading to a disruption of redox signaling and molecular damage [103]. Oxidative stress enhances the atherosclerotic process by inducing an endothelial dysfunction and subsequently predisposes NAFLD subject to

cardiovascular events [104]. In addition, it leads to impairment in mitochondrial function, which is associated with both insulin resistance and atherosclerosis [105].

A high production of prothrombotic factors, mainly factors VII, IX, XI and XII, has been shown to be linked to NAFLD [106] and therefore can contribute to an increase in cardiovascular risk and atherosclerosis in these patients [107]. In the same context, increased evidence supports the positive relationship between circulating levels of plasminogen inhibitor activator 1 (PAI-1) and hepatic fat content and NAFLD severity [108]. An increased release of the PAI is known to be a good predictor of ischemic heart disease [109].

3.3.4. Predictors of Cardiac Events in NAFLD

In recent years, novel hepatic tissue-specific molecules known as hepatokines have been described to determine cardiovascular effects. Fibroblast growth factor 21 (FGF-21) is a peptide predominantly produced and secreted by the liver and correlates with hepatic fat content and the severity of NAFLD [110]. Elevated FGF-21 serum levels have been shown to be associated with atherosclerosis [111], and coronary heart disease [112]. NAFLD has been related with higher

serum levels of another hepatokine known as Fetuin-A (FetA) [113]. FetA plasma levels have been shown to be positively related with negative cardiovascular outcomes as well as endothelial dysfunction and myocardial infarction [114].

Given the rapidly growing global burden of NAFLD and limitations of performing liver biopsy due to interobserver variability and procedure-related morbidity and mortality, recent recommendations suggested several noninvasive markers of fibrosis and steatosis [115]. The NAFLD Fibrosis Score (NFS) is a simple, serum-based index, originally developed for the diagnosis of advanced hepatic fibrosis in patients with NAFLD representing an independent predictor for overall cardiovascular events and mortality, including cardiac death [116].

3.3.5. Management

The main clinical recommendations for the management of NAFLD include lifestyle modifications through a combination of physical activity, smoking cessation, appropriate dietary changes, and gradual weight loss. This approach has demonstrated to be an effective tool to improve the cardiovascular risk profile in NAFLD patients.

Moreover, current guidelines recommend careful clinical screening and treatment for associated cardiometabolic risk factors including

obesity, diabetes mellitus, dyslipidemia, and hypertension in all individuals with NAFLD. Bariatric surgery represents a recommended choice for morbidly obese individuals if lifestyle modifications and pharmacological approach have not yielded long-term success. It provides cardiovascular benefits in terms of reducing overall mortality by improving hepatic inflammation, metabolic syndrome components, and cardiac morphology [96,117].

4. The Heart–Liver Axis

Increasing evidence suggests that the heart synthesizes and secretes proteins referred to as cardiokines, which are involved in the inter-cellular and inter-organ communication [118]. More than 16 cardiokines have been identified, including the atrial natriuretic factor (ANF), BNP, transforming growth factor- β 1 (TGF- β 1), angiotensin II, and proinflammatory cytokines which are known to play physiological and pathological role in cardiac fibrosis, apoptosis, and metabolism [119].

It has been reported that cardiokines not only have local involvement in the stress response and damage repair, but also mediate several regulatory effects on extra-cardiac tissues [120]. In the same context, ANP, a well know cardiokine secreted from the cardiac tissue and

known to mediate fluid homeostasis in heart failure, has been shown to attenuate glycolysis and increased gluconeogenesis in rat liver [121].

NOD-like receptor protein 3 (NLRP3) inflammasome is the most widely studied inflammasome in myocardial tissue. It consists of a multi-protein signaling platform that acts as an intracellular innate immune sensor and its activation induces the transcription, maturation, and release of proinflammatory cytokines, in particular IL-1 β and IL-18. In heart failure, three main triggers contribute to the activation of NLRP3 inflammasome components: adenosine triphosphate (ATP), mitochondrial DNA (mtDNA), and reactive oxygen species (ROS) [122]. Despite the clear evidence that cardiokines are involved in the crosstalk between myocardial inflammation in heart failure and peripheral tissue damage in some organs (adipose, tissue, skeletal muscle, spleen, and kidney), direct mechanisms linking heart and liver disease remain not fully characterized. In animal model, congestive heart failure has been shown to be associated with altered metabolism and proinflammatory response in liver [123]. In this study, the serum concentration and hepatic gene expression of proinflammatory cytokines TNF- α and IL-1 β significantly increased in

the case of congestive heart failure. In addition, blood levels of hepatic proteins, such as albumin, transthyretin, transferrin, and retinol-binding protein, were decreased. In congestive heart failure rats, the gene expression of enzymes related to lipogenesis was increased, while that related to gluconeogenesis was decreased. In addition, during fasting, the liver of heart failure rats showed a maladaptive response by incorporating more glucose instead of releasing energy substrates [123], probably because of state of liver inflammation.

Olson's group reported that the heart controls systemic energy metabolism, fat mass, and body weight via the heart specific microRNA-208a (miR-208a) and Mediator complex subunit 13 (MED13) signaling in rodent cardiomyocytes [124]. MiR-208a is encoded by an intron of the α -cardiac muscle myosin heavy chain gene (Myh6) and is expressed specifically in the heart. MiR-208a is mainly involved in cardiac remodeling and regulation of cardiac hypertrophy pathway. MED13 is a mediator of transcription machinery and contributes to cardiac and systemic metabolism by controlling gene expression and mitochondrial numbers through thyroid hormone receptors and other nuclear hormones [125].

Overexpression of MED13 or inhibition of miR-208a in cardiac tissue of transgenic mice has been shown to enhance lipid uptake, β -oxidation, mitochondrial content, and other genes involved in fatty acids utilization in adipose tissue and liver. These findings support the existence of a metabolic crosstalk between heart and liver [126].

The co-existence of bidirectional communication was also confirmed in patients with heart failure [127]. Impaired left ventricular function was associated with a decrease of endogenous hepatic unsaturated fatty acids circulatory levels. It was hypothesized that an increased left ventricular wall stress and pulmonary pressure can be transmitted to the liver veins and cause hepatic congestion and consequently may alter the fatty acid profile in the liver [127]. On the other hand, reduced levels of unsaturated fatty acids were correlated with adverse cardiac consequences, probably by interfering with proinflammatory processes such as nuclear factor κ B (NF- κ B) activation and TNF- α release [127,128].

Chapter: 3

Subjects and Methods

3. Subjects and Methods:

3.1 Study protocol:

The study was a clinical cross-sectional study performed on patients with heart failure admitted to the Department of Medicine at several private and public hospitals in Sana'a city between July 1, 2021 and December 31, 2021.

3.2 Study population:

The study population constitutes 162 patients who were suffering from heart failure with help of echocardiographic assessment, namely, with reduced ejection fraction (40%). Patients were enrolled in the study after doing the required laboratory and radiological assessment including ultrasound abdomen, echocardiogram (ejection fraction and diastolic dysfunction grading) after strict adherence to the inclusion and exclusion criteria. An oral consent was obtained from all patients after explaining the aims and the nature of the study which does not interfere with their clinical management.

3.3 Data collection:

The collected data included age, smoking, alcohol, clinical presentation, diagnostic radiological and laboratory tests as well as

the medical treatment. Patients were first asked about the personal details and then were asked about specific symptoms of dyspnoea, orthopnoea, chest pain, fatiguability, exercise intolerance, ankle edema, jaundice, abdominal distension, dilated neck veins and night coughs. They were enquired about their previous hospitalizations, drug intake, liver diseases, blood transfusions, alcoholism and treatment history. Then the patient was examined for elevation in jugular venous pressure, low blood pressure, tachycardia along with the routine general examination.

Other examinations included looking for congestive liver enlargement, pleural effusion along with the laboratory investigations of complete blood count, urine routine tests, renal function and special emphasis was laid on liver function tests including serum AST, ALT, ALP, bilirubin, albumin, prothrombine time, activated partial thromboplastin time. Abdominal ultrasound was done to assess liver while echocardiogram was done to diagnose heart failure with reduced and preserved ejection fraction.

3.4 Inclusion and exclusion criteria

Inclusion criteria:

- Acute heart failure

- Chronic heart failure

Exclusion criteria:

- Primary liver disease including infective liver diseases
- Cirrhotic patients
- Malignancy
- Alcoholics

3.5 Statistical analysis:

Statistical analysis was performed using Statistical Package for Social Science software (SPSS, version 15). The Shapiro-Wilk test for normality was used to determine if the continuous variables had normal or abnormal distributions, while one-way analysis of variance (ANOVA) and paired-sample t-tests were used for the normally distributed continuous variables. The Kruskal-Wallis test was used to analyze the abnormally distributed continuous variables. When the Kruskal-Wallis test indicated statistically significant differences, the causes of those differences were determined using a Bonferroni adjusted Mann-Whitney U test.

Chapter: 4

Results

4. Results

4.1. Demographic data:

4.1.1 Gender distribution:

A total of 162 diagnosed cases of cardiohepatic syndrome were studied. Male patients were 117 (72.2%) and female patients were 45 (27.8%). The gender distribution of the sample is represented in Table (1) and graphically illustrated in Figure (1).

Table (1): Gender distribution of cardiohepatic syndrome patients:

	Frequency	Percent
Male	117	72.2
Female	45	27.8
Total	162	100.0




Figure (1): Gender distribution of cardiohepatic syndrome patients

4.1.2 Age distribution:

The age of patients with cardiohepatic syndrome ranged

between 0.5 and 81 years. The results of the present study showed that most patients with cardiohepatic syndrome aged between 41 and 70 years (66.1%). The age distribution of the sample is represented in Table (2) and graphically illustrated in Figure (2).

Table (2): Age distribution of cardiohepatic syndrome patients:

Age categories (years)	Frequency	Percent
0.5-10	7	4.3
11-20	6	3.7
21-30	12	7.4
31-40	18	11.1
41-50	35	21.6
51-60	38	23.5
61-70	34	21.0
71-80	11	6.8
81-90	1	0.6
Total	162	100.0




Figure (2): Age distribution of cardiohepatic syndrome patients

4.1.3 Health facilities distribution:

Most cardiohepatic syndrome patients were admitted to Lebanon hospital (75.3%) followed by Althawra hospital (10.5%). Additional 5 public and private hospitals were included in the present study. Results are represented in **Table (3)** and graphically illustrated in **Figure (3)**.

Table (3): Health facilities distribution of cardiohepatic syndrome patients:

	Frequency	Percent
Lebanon Hospital	122	75.3
Althawra Hospital	17	10.5
Republican Hospital	6	3.7
UST hospital	2	1.2
European hospital	4	2.5
48 Hospital	9	5.6
Kuwait Hospital	2	1.2
Total	162	100.0




Figure (3): Health facilities distribution of cardiohepatic syndrome patients

4.2 Clinical presentation of cardiohepatic syndrome:

4.2.1 Signs:

Patients with cardiohepatic syndrome most frequently presented with edema (56.2%), pallor (40.7%), and cyanosis (25.3%). Other less frequent signs were icterus (8.6%) and clubbing (8%). Results are represented in Table (4) and graphically illustrated in Figure (4).

Table (4): Clinical signs in patients with cardiohepatic syndrome:

	Frequency	Percent
pallor	27	16.9
icterus	5	2.8
cyanosis	25	15.5
clubbing	2	1.4
edema	48	29.6
pallor + icterus	5	2.8
pallor + cyanosis	5	2.8
pallor + edema	21	12.7
icterus + edema	2	1.4
cyanosis + clubbing	2	1.4
cyanosis + edema	7	4.2
clubbing + edema	5	2.8
pallor + icterus + edema	2	1.4

pallor + cyanosis + edema	2	1.4
pallor + clubbing + edema	2	1.4
pallor + icterus + clubbing + edema	2	1.4
Total	162	100.0




Figure (4): Clinical signs in patients with cardiohepatic syndrome

4.2.2 Blood pressure and pulse findings:

The average pulse rates in cardiohepatic syndrome patients was 94 ppm (maximum 142 and 37 minimum), the average systolic blood pressure was 118mmHg (maximum 200 and 60 minimum), and the average diastolic blood pressure was 75 mmHg (maximum 120 and minimum 40). Results are represented in **Table (5)** and graphically illustrated in **Figure (5)**.

Table (5): Blood pressure and pulse findings in cardiohepatic patients:

	Minimum	Maximum	Mean	Std. Deviation
Pulse rate	37.00	142.00	94.4487	18.38628
Systolic BP	60.00	200.00	118.4904	26.10718
Diastolic BP	40.00	120.00	74.7452	15.15895




Figure (5): Blood pressure and pulse findings in cardiohepatic patients

4.2.3 Laboratory tests findings:

The laboratory investigations that were performed for the patients to assess liver function included Total bilirubin, Direct bilirubin, Indirect bilirubin, AST, ALT, ALP, Total protein, Albumin, Prothrombin time, and Activated partial thromboplastin time. Additionally, routine complete blood count and kidney function tests were performed. Results are represented in Table (6).

Table (6): Laboratory tests findings in cardiohepatic patients:

	Minimum	Maximum	Mean	Std. Deviation
Total bilirubin	.05	24.00	2.1225	4.54792
Direct bilirubin	.00	9.20	1.2823	2.30490

Indirect bilirubin	.10	148.00	4.3294	21.82649
AST	10.00	1974.70	101.5303	205.10275
ALT	10.00	1238.00	88.7389	186.71784
ALP	23.00	543.00	157.1923	101.75365
Total protein	7.73	134.00	72.9956	22.18229
Albumin	1.90	37.00	5.2592	5.92182
Prothrombin time	11.10	142.00	23.9907	27.19077
Activated partial thromboplastin time	13.00	120.00	38.8000	12.82471
Hemoglobin	8.00	20.20	13.1180	2.42816
Platelets	40.00	705.00	279.4934	120.84580
Serum urea	3.60	101.00	37.9434	20.77417
Serum creatinine	.20	160.00	2.4762	13.61067

Table (7) below shows the result of the liver function tests,

Among the total HF cases 162 more than 50% of them there was no records for the result of the bilirubin while there were records for only 80 patients (49%). Within those who have recorded results for the total bilirubin, 24% of them were abnormal results. Regarding to the result of the AST, the result showed that among those who had recorded results 151, around 40% of them had AST above than the normal range. Also the result of the ALT showed that, among those who had recorded results around 37% of them had ALT above than the normal range. Regarding to the result of the ALP, those who had recorded results for the ALP were only 52 (32%) of the total participants. Among those who had recorded results more than half of them 27 (54%) had abnormal ALP.

Table (7): The result of the liver function tests in cardiohepatic patients

	Recorded	Not	Total
--	----------	-----	-------

	Normal		Abnormal		Total recorded	recorded	
	Frequency	%	Frequency	%			
Total bilirubin	61	76%	19	24%	80	82	162
AST	90	60%	61	40%	151	9	162
ALT	99	63%	58	37%	157	5	162
ALP	25	46%	27	54%	52	110	162
Total protein	30	60%	20	40%		112	162
Albumin	36	67%	18	33%		108	162

4.2.4 Classification of heart failure according to ejection fraction:

Large proportion of patients (55.7%) had heart failure with preserved ejection fraction (HFpEF) while 28.2% of the patients had heart failure with reduced ejection fraction (HFrEF). Minority (9.9%) of the patients had heart failure with mid-range ejection fraction (HFmrEF) and 6.1% of the patients had normal ejection fraction. Results are represented in Table (7) and graphically illustrated in Figure (6).

Table (8): Classification of heart failure according to ejection fraction:

	Frequency	Percent
HFrEF	46	28.2
HFmrEF	16	9.9
HFpEF	90	55.7
Normal EF	10	6.1
Total	162	100.0




Figure (6): Classification of heart failure according to ejection fraction

Chapter: 5

Discussion

5. Discussion

The term cardiac hepatopathy (CH) describes liver damage caused by cardiac disorders. CH consists of congestive hepatopathy and acute cardiogenic liver injury (ACLI) [129]. Congestive hepatopathy usually occurs in chronic heart failure as a result of increased hepatic venous pressure, decreased hepatic blood flow, and a decrease in arterial oxygen saturation [130].

Cardio-Hepatic Interaction: The relation between chronic heart failure and liver injury has been well described [131,132]. The liver receives 25% of the total cardiac output (CO), although it accounts for only 2.5% of the total body weight [133]. The hepatic arteries blood, which is characterized with high pressure and is well oxygenation, supplies only about one fifth to one third of the total liver blood flow. The approximate other two thirds supplied by the low pressure, less oxygenate blood of the portal venous. [134] The hepatic artery autoregulation caused by hepatic arterial buffer response may compensate for a 25–60% reduction in portal blood flow. On the contrary, in case of a decrease in hepatic blood flow, the portal vein depends on the hepatic-portal venous pressure gradient and on the mesenteric circulation. The dual liver vasculature protects the liver

from hypoperfusion as it is particularly sensitive to perfusion changes [130].

The cardio-hepatic relationship initially has been described in 1833 by Kiernan, who coined the term of a post-mortem congested “nutmeg” liver in patients with heart failure [135]. In 1951, Sherlock et al., described the findings of hepatic cell necrosis in every form of heart failure. He claimed that anoxia causes the degeneration of central liver cells and the dilatation of sinusoids. Centrilobular necrosis may be caused by increased pressure in the hepatic veins [136]. Chronic right heart failure may lead to CH, which is mainly caused by the passive congestion of the liver and results in elevated CVP [137]. Different etiologies for right-sided heart failure may precipitate CH, including constrictive pericarditis, mitral stenosis, tricuspid regurgitation, cardiomyopathy, and cor pulmonale. There are also congenital heart diseases related to elevated CVP and passive congestion as atrial and ventricular septal defect, Ebstein anomaly, etc. [138]. Patients with abnormal liver enzymes and right-side heart failure or any cause of elevated central pressure should be suspected of CH. Coexistence of the left and right-side heart failure results in reduced CO and arterial perfusion and venous congestion, worsening

liver injury [129,139].

Acute Cardiogenic Liver Injury (ACLI): Due to the liver-enhanced sensitivity to perfusion changes, acute circulatory changes, related to acute decompensated heart failure; acute MI; myocarditis; massive PE, or cardiogenic shock, might result in ACLI [140]. The pathogenesis of ACLI includes a decrease in CO and tissue perfusion, hypoxemia, and passive venous congestion. The histologic appearance of ACLI is characterized by necrosis of pericentral zone 3 hepatocytes, which received poorly oxygenated blood compared with zones 1 and 2. ACLI is usually asymptomatic at the beginning, but 2–24 h after acute insult, patients may suffer from nausea, vomiting, right upper quadrant pain, and apathy. In rare cases, mental confusion, jaundice, and even hepatic coma may develop [134]. The common laboratory findings in ACLI are elevated transaminases and LDH, which reach their peak in 1–3 days after the acute insult, and in case of improvement, return to the normal limits within 7–10 days after [129].

Few studies evaluated the cardio-hepatic relation in acute cardiac injury, as occur in patients with STEMI. Ming et al. studied STEMI patients with no preexisting liver disease, who underwent primary PCI.

They showed that serum transaminases ≥ 95 th percentile were associated with increased incidence of short- and long-term all-cause mortality [141]. A recent study on patients with STEMI who underwent primary PCI demonstrated that combined ALKP and hypoxic liver injury (HLI) in addition was associated with poor clinical outcomes [142]. Another retrospective study of STEMI patients who underwent primary PCI with no preexisting liver disease, found the presence of HLI correlated with HFREF and associated with poor survival [143]. Another study showed that increased ALK-P was associated with higher in-hospital event rates in patients with STEMI who underwent primary PCI [144]. On the other hand, in patients with STEMI, the presence of elevated GGT is associated with long-term mortality after 30 days after PCI [145]. Post hoc analysis of survival showed that liver function impairment was associated with a 50% increase in the 180-day mortality rate in patients with acute decompensated heart failure and required inotrope treatment. Authors suggested the high level of ALK-P and/or transaminases apparently reflected the severity of the underline HF [146].

A possible mechanism for liver injury is elevated hydrostatic pressure related to liver sinusoids which might cause bile canaliculi and

ductulus compression. In addition, hepatic cytolysis may be secondary to the hypoperfusion/hypo-oxygenation of the centrilobular region. A 46–76% liver function abnormality was reported in patients with acute heart failure, suggesting to measure the baseline liver function test of patients present with acute decompensated heart failure and, in addition, to consider adding it to future HF guidelines [147].

The Impact of Liver Injury on the Heart: Cirrhotic cardiomyopathy is the concomitant cardiac dysfunction in patients with cirrhosis and having hyperdynamic systemic circulation, characterized by an increased heart rate and cardiac output, and a decreased arterial blood pressure and systemic vascular resistance [148]. In addition, there is an increased cardiac pre-load and right atrial pressure, cardiac contractile impairment, diastolic dysfunction, and electrophysiological disorders such as prolonged Q- T interval. Cardiac morphometric changes are associated with the severity of liver failure regardless of liver cirrhosis etiology [149]. The prevalent of diastolic dysfunction in cirrhosis may be up to 50% and correlate with severity of cirrhosis, complication, and death [149–151].

Patients with acute liver failure (ALF) caused by different etiologies

such as viral hepatitis and acetaminophen-induced, may have an elevation of troponin I levels which reflect myocardial cell damage. The exact mechanism of that unrecognized cardiac injury and potential of reversibility is not clear. The subclinical myocardial injury in patients with ALF is associated with higher morbidity and mortality rates [152]. Critically ill noncardiac patients may develop myocardial oxygen supply and demand imbalance, which may result in a higher level of troponin I and associated with elevation of Interleukin 6, Tumor necrosis factor-alpha (TNF- α), and CRP. TNF- α is known to be able to depress myocardial function and induce the apoptosis of cardiomyocytes and may lead to reduced coronary artery flow and EF [153]. In patients with an acute cardiac insult (e.g., STEMI), sequential liver function tests taken throughout the hospitalization may alert clinicians to liver enzyme abnormalities which were associated with poorer cardiac presentation (low cardiac output and/or signs of venous congestion). In addition to the possible relation to patients' outcomes, a clinical decision of withholding hepatotoxic drugs earlier should be considered [154,155]. This offers a non-invasive and simple way to risk stratify patients, which should be further validated in prospective studies.

Chapter: 6

Summary and Conclusions

6. Summary and Conclusions

6.1. Summary:

The present study was aimed to investigate the clinical patterns of cardiohepatic syndrome among patients with heart failure attending several private and public hospitals in Sana'a city, Yemen. The study was a clinical cross-sectional study performed on patients with heart failure admitted to the medical departments at several private and public hospitals in Sana'a city between July 1, 2021 and December 31, 2021.

A total of 162 diagnosed cases of cardiohepatic syndrome were studied. Male patients were 177 (72.2%) and female patients were 45 (27.8%). The age of patients with cardiohepatic syndrome ranged between 0.5 and 81 years. The results of the present study showed that most patients with cardiohepatic syndrome aged between 41 and 70 years (66.1%). Most cardiohepatic syndrome patients were admitted to Lebanon hospital (75.3%) followed by Althawra hospital (10.5%). Patients with cardiohepatic syndrome most frequently presented with edema (56.2%), pallor (40.7%), and cyanosis (25.3%). Other less frequent signs were icterus (8.6%) and clubbing (8%). The average pulse rates in cardiohepatic syndrome

patients was 94 ppm (maximum 142 and 37 minimum), the average systolic blood pressure was 118mmHg (maximum 200 and 60 minimum), and the average diastolic blood pressure was 75 mmHg (maximum 120 and minimum 40). The laboratory investigations that were performed for the patients to assess liver function included Total bilirubin, Direct bilirubin, Indirect bilirubin, AST, ALT, ALP, Total protein, Albumin, Prothrombin time, and Activated partial thromboplastin time. Additionally, routine complete blood count and kidney function tests were performed. Large proportion of patients (55.7%) had heart failure with preserved ejection fraction (HFpEF) while 28.2% of the patients had heart failure with reduced ejection fraction (HFrEF). Minority (9.9%) of the patients had heart failure with mid-range ejection fraction (HFmrEF) and 6.1% of the patients had normal ejection fraction.

6.2 Conclusions:

From the results of the present study, it could be concluded that:

- Cardiohepatic syndrome is more prevalent in male heart failure patients.
- Middle-aged patients are more prone to cardiohepatic syndrome

and the detrimental effects of heart failure on liver functions.

- Cardiohepatic syndrome presents with full-range of signs, symptoms, and lab test deviations.
- Cardiohepatic syndrome is more likely in patients with reduced ejection fraction (HFrEF).
- Proper assessment of cardiohepatic syndrome could play significant roles in prognosis of heart failure and other associated comorbidities as most drugs are metabolized in liver.

Chapter: 7

References

7. References

1. Khadem E., Toosi M.N., Ilkhani R. Liver- Heart Inter- Relationship in Fatty Liver Disease Based on the Avicenna's Point of View. Iran. J. Public Health. 2013;42:648–649. [PMC free article] [PubMed] [Google Scholar]
2. Asrani N.S., Freese D.K., Phillips S.D., Heimbach J., Asrani S.K., Warnes C.A., Kamath P.S. Congenital heart disease and the liver. Hepatology. 2012;56:1160–1169. doi: 10.1002/hep.25692. [PubMed] [CrossRef] [Google Scholar]
3. Giallourakis C.C., Rosenberg P.M., Friedman L.S. The liver in heart failure. Clin. Liver Dis. 2002;6:947–967. doi: 10.1016/S1089-3261(02)00056-9. [PubMed] [CrossRef] [Google Scholar]
4. De Gonzalez A.K.K., Lefkowitz J.H. Heart Disease and the Liver. Gastroenterol. Clin. N. Am. 2017;46:421–435. doi: 10.1016/j.gtc.2017.01.012. [PubMed] [CrossRef] [Google Scholar]
5. Myers R.P., Cerini R., Sayegh R., Moreau R., Degott C., Lebrec D., Lee S.S. Cardiac hepatopathy: Clinical, hemodynamic, and histologic characteristics and correlations. Hepatology. 2003;37:393–400. doi: 10.1053/jhep.2003.50062. [PubMed] [CrossRef] [Google Scholar]
6. Téllez L., Rodriguez-Santiago E., Albillos A. Fontan-Associated Liver Disease: A Review. Ann. Hepatol. 2018;17:192–204. doi: 10.5604/01.3001.0010.8634. [PubMed] [CrossRef] [Google Scholar]
7. Fauci A.S., Braunwald E., Hauser S.L., Longo D.L., Jameson J., Loscalzo J. Harrison's Principles of Internal Medicine. Volume 2 McGraw-Hill Medical; New York, NY, USA: 2008. [Google Scholar]
8. Kiesewetter C.H., Sheron N., Vettukattill J.J., Hacking N., Stedman B., Millward-Sadler H., Haw M., Cope R., Salmon A.P., Sivaprakasam M.C., et al. Hepatic changes in the failing Fontan circulation. Heart. 2006;93:579–584. doi: 10.1136/hrt.2006.094516. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Weisberg I.S., Jacobson I.M. Cardiovascular Diseases and the Liver. Clin. Liver Dis. 2011;15:1–20. doi: 10.1016/j.cld.2010.09.010. [PubMed] [CrossRef] [Google Scholar]
10. Vasconcelos L.A.B.A., De Almeida E.A., Bachur L.F. Clinical evaluation and hepatic laboratory assessment in individuals with congestive heart failure. Arq. Bras. Cardiol. 2007;88:590–595. doi: 10.1590/S0066-782X2007000500015. [PubMed] [CrossRef] [Google Scholar]
11. Poelzl G., Eberl C., AchRAINER H., Doerler J., Pachinger O., Frick M., Ulmer H. Prevalence and Prognostic Significance of Elevated γ -Glutamyltransferase in Chronic Heart Failure. Circ. Heart Fail. 2009;2:294–302.

- doi: 10.1161/CIRCHEARTFAILURE.108.826735. [PubMed] [CrossRef] [Google Scholar]
12. Fuhrmann V., Jäger B., Zubkova A., Drolz A. Hypoxic hepatitis – epidemiology, pathophysiology and clinical management. *Wien. Klin. Wochenschr.* 2010;122:129–139. doi: 10.1007/s00508-010-1357-6. [PubMed] [CrossRef] [Google Scholar]
13. Dunn G.D., Hayes P., Breen K.J., Schenker S. The liver in congestive heart failure: A review. *Am. J. Med. Sci.* 1973;265:174–189. doi: 10.1097/00000441-197303000-00001. [PubMed] [CrossRef] [Google Scholar]
14. Shah H., Kuehl K., Sherker A.H. Liver Disease After the Fontan Procedure. *J. Clin. Gastroenterol.* 2010;44:1. doi: 10.1097/MCG.0b013e3181d476fc. [PubMed] [CrossRef] [Google Scholar]
15. Wells M.L., Fenstad E.R., Poterucha J.T., Hough D.M., Young P.M., Araoz P.A., Ehman R.L., Venkatesh S.K. Imaging Findings of Congestive Hepatopathy. *Radiographics.* 2016;36:1024–1037. doi: 10.1148/rg.2016150207. [PubMed] [CrossRef] [Google Scholar]
16. Dai D.-F., Swanson P., Krieger E., Liou I.W., Carithers R.L., Yeh M.M. Congestive hepatic fibrosis score: A novel histologic assessment of clinical severity. *Mod. Pathol.* 2014;27:1552–1558. doi: 10.1038/modpathol.2014.79. [PubMed] [CrossRef] [Google Scholar]
17. Sherlock S. The Liver in Heart Failure Relation of Anatomical, Functional, and Circulatory Changes. *Heart.* 1951;13:273–293. doi: 10.1136/hrt.13.3.273. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Maleki M., Vakilian F., Amin A. Liver diseases in heart failure. *Heart Asia.* 2011;3:143–149. [PMC free article] [PubMed] [Google Scholar]
19. Russell S.D., Rogers J., Milano C.A., Dyke D.B., Pagani F.D., Aranda J.M., Klodell C.T., Boyle A.J., John R., Chen L., et al. Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device. *Circulation.* 2009;120:2352–2357. doi: 10.1161/CIRCULATIONAHA.108.814863. [PubMed] [CrossRef] [Google Scholar]
20. Dichtl W., Vogel W., Dunst K.M., Grander W., Alber H.F., Frick M., Antretter H., Laufer G., Pachinger O., Pölzl G. Cardiac hepatopathy before and after heart transplantation. *Transpl. Int.* 2005;18:697–702. doi: 10.1111/j.1432-2277.2005.00122.x. [PubMed] [CrossRef] [Google Scholar]
21. Seeto R.K., Fenn B., Rockey D.C. Ischemic hepatitis: Clinical presentation and pathogenesis. *Am. J. Med.* 2000;109:109–113. doi: 10.1016/S0002-

- 9343(00)00461-7. [PubMed] [CrossRef] [Google Scholar]
22. Harjola V.-P., Mullens W., Banaszewski M., Bauersachs J., Rocca H.-P.B.-L., Chioncel O., Collins S.P., Doehner W., Filippatos G.S., Flammer A., et al. Organ dysfunction, injury and failure in acute heart failure: From pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Eur. J. Heart Fail. 2017;19:821–836. doi: 10.1002/ehhf.872. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
23. Eipel C., Abshagen K., Vollmar B. Regulation of hepatic blood flow: The hepatic arterial buffer response revisited. World J. Gastroenterol. 2010;16:6046–6057. doi: 10.3748/wjg.v16.i48.6046. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Henrion J., Descamps O., Luwaert R., Schapira M., Parfonry A., Heller F. Hypoxic hepatitis in patients with cardiac failure: Incidence in a coronary care unit and measurement of hepatic blood flow. J. Hepatol. 1994;21:696–703. doi: 10.1016/S0168-8278(94)80226-2. [PubMed] [CrossRef] [Google Scholar]
25. Naschitz J.E., Yeshurun D., Shahar J. Cardiogenic Hepatorenal Syndrome. Angiology. 1990;41:893–900. doi: 10.1177/000331979004101101. [PubMed] [CrossRef] [Google Scholar]
26. Birrer R., Takuda Y., Takara T. Hypoxic hepatopathy: Pathophysiology and prognosis. Intern. Med. 2007;46:1063–1070. doi: 10.2169/internalmedicine.46.0059. [PubMed] [CrossRef] [Google Scholar]
27. Henrion J., Schapira M., Luwaert R., Colin L., Delannoy A., Heller F.R. Hypoxic hepatitis: Clinical and hemodynamic study in 142 consecutive cases. Medicine. 2003;82:392–406. doi: 10.1097/01.md.0000101573.54295.bd. [PubMed] [CrossRef] [Google Scholar]
28. Denis C., De Kerguennec C., Bernuau J., Beauvais F., Cohen-Solal A. Acute hypoxic hepatitis ('liver shock'): Still a frequently overlooked cardiological diagnosis. Eur. J. Heart Fail. 2004;6:561–565. doi: 10.1016/j.ejheart.2003.12.008. [PubMed] [CrossRef] [Google Scholar]
29. Giannini E.G., Testa R., Savarino V. Liver enzyme alteration: A guide for clinicians. Can. Med. Assoc. J. 2005;172:367–379. doi: 10.1503/cmaj.1040752. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
30. Cassidy W.M., Reynolds T.B. Serum Lactic Dehydrogenase in the Differential Diagnosis of Acute Hepatocellular Injury. J. Clin. Gastroenterol. 1994;19:118–121. doi: 10.1097/00004836-199409000-00008. [PubMed] [CrossRef] [Google Scholar]

31. Alvarez A.M., Mukherjee D. Liver Abnormalities in Cardiac Diseases and Heart Failure. *Int. J. Angiol.* 2011;20:135–142. doi: 10.1055/s-0031-1284434. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. De La Monte S.M., Arcidi J.M., Moore G.W., Hutchins G.M. Midzonal Necrosis as a Pattern of Hepatocellular Injury After Shock. *Gastroenterology.* 1984;86:627–631. doi: 10.1016/S0016-5085(84)80109-2. [PubMed] [CrossRef] [Google Scholar]
33. Waseem N., Chen P.-H. Hypoxic Hepatitis: A Review and Clinical Update. *J. Clin. Transl. Hepatol.* 2016;4:263–268. [PMC free article] [PubMed] [Google Scholar]
34. Limas C.J., Guiha N.H., Lekagul O., Cohn J.N. Impaired Left Ventricular Function in Alcoholic Cirrhosis with Ascites. *Circulation.* 1974;49:755–760. doi: 10.1161/01.CIR.49.4.755. [PubMed] [CrossRef] [Google Scholar]
35. Møller S., Henriksen J.H. Cirrhotic cardiomyopathy. *J. Hepatol.* 2010;53:179–190. doi: 10.1016/j.jhep.2010.02.023. [PubMed] [CrossRef] [Google Scholar]
36. Alqahtani S.A., Fouad T.R., Lee S.S. Cirrhotic Cardiomyopathy. *Semin. Liver Dis.* 2008;28:59–69. doi: 10.1055/s-2008-1040321. [PubMed] [CrossRef] [Google Scholar]
37. Wiese S., Hove J., Bendtsen F., Møller S. Cirrhotic cardiomyopathy: Pathogenesis and clinical relevance. *Nat. Rev. Gastroenterol. Hepatol.* 2013;11:177–186. doi: 10.1038/nrgastro.2013.210. [PubMed] [CrossRef] [Google Scholar]
38. Goldberg D., Fallon M.B. The Art and Science of Diagnosing and Treating Lung and Heart Disease Secondary to Liver Disease. *Clin. Gastroenterol. Hepatol.* 2015;13:2118–2127. doi: 10.1016/j.cgh.2015.04.024. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
39. Bolognesi M., Di Pascoli M., Verardo A., Gatta A. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. *World J. Gastroenterol.* 2014;20:2555–2563. doi: 10.3748/wjg.v20.i10.2555. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
40. Møller S. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. *Heart.* 2002;87:9–15. doi: 10.1136/heart.87.1.9. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
41. Henriksen J.H., Fuglsang S., Bendtsen F., Christensen E., Møller S. Arterial compliance in patients with cirrhosis: Stroke volume-pulse pressure ratio as simplified index. *Am. J. Physiol. Liver Physiol.* 2001;280:G584–G594. doi: 10.1152/ajpgi.2001.280.4.G584. [PubMed] [CrossRef] [Google Scholar]
42. Dümcke C.W., Møller S. Autonomic dysfunction in cirrhosis and portal

- hypertension. *Scand. J. Clin. Lab. Investig.* 2008;68:437–447. doi: 10.1080/00365510701813096. [PubMed] [CrossRef] [Google Scholar]
43. Kelbæk H., Rabøl A., Brynjolf I., Eriksen J., Bonnevie O., Godtfredsen J., Munck O., Lund J.O. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. *Clin. Physiol.* 1987;7:35–41. doi: 10.1111/j.1475-097X.1987.tb00631.x. [PubMed] [CrossRef] [Google Scholar]
44. Møller S., Dümcke C.W., Krag A. The heart and the liver. *Expert. Rev. Gastroenterol. Hepatol.* 2009;3:51–64. doi: 10.1586/17474124.3.1.51. [PubMed] [CrossRef] [Google Scholar]
45. Lee S.S., Marty J., Mantz J., Samain E., Braillon A., Lebrech D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. *Hepatology.* 1990;12:481–485. doi: 10.1002/hep.1840120306. [PubMed] [CrossRef] [Google Scholar]
46. Hausdorff W.P., Caron M.G., Lefkowitz R.J. Turning off the signal: Desensitization of beta-adrenergic receptor function. *FASEB J.* 1990;4:2881–2889. doi: 10.1096/fasebj.4.11.2165947. [PubMed] [CrossRef] [Google Scholar]
47. Van Obbergh L., Vallieres Y., Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. *J. Hepatol.* 1996;24:747–752. doi: 10.1016/S0168-8278(96)80272-8. [PubMed] [CrossRef] [Google Scholar]
48. Liu H., Ma Z., Lee S.S. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. *Gastroenterology.* 2000;118:937–944. doi: 10.1016/S0016-5085(00)70180-6. [PubMed] [CrossRef] [Google Scholar]
49. Gaskari S.A., Liu H., Moezi L., Li Y., Baik S.K., Lee S.S. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. *Br. J. Pharmacol.* 2005;146:315–323. doi: 10.1038/sj.bjp.0706331. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
50. Basu P.P., Aloysius M.M., Shah N.J., Brown R.S., Jr. Review article: The endocannabinoid system in liver disease, a potential therapeutic target. *Aliment. Pharmacol. Ther.* 2014;39:790–801. doi: 10.1111/apt.12673. [PubMed] [CrossRef] [Google Scholar]
51. Bátkai S., Mukhopadhyay P., Harvey-White J., Kechrid R., Pacher P., Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. *Am. J. Physiol. Circ. Physiol.* 2007;293:H1689–H1695. doi: 10.1152/ajpheart.00538.2007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Yang Y.Y., Liu H., Nam S.W., Kunos G., Lee S.S. Mechanisms of TNF α -

- induced cardiac dysfunction in cholestatic bile ductligated mice: Interaction between TNF α and endocannabinoids. *J. Hepatol.* 2010;53:298–306. doi: 10.1016/j.jhep.2010.03.011. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
53. Naylor M., Cooper L.L., Enserro D.M., Xanthakis V., Larson M.G., Benjamin E.J., Aragam J., Mitchell G.F., Vasan R.S. Left Ventricular Diastolic Dysfunction in the Community: Impact of Diagnostic Criteria on the Burden, Correlates, and Prognosis. *J. Am. Heart Assoc.* 2018;7:e008291. doi: 10.1161/JAHA.117.008291. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Baik S.K., Fouad T.R., Lee S.S. Cirrhotic cardiomyopathy. *Orphanet J. Rare Dis.* 2007;2:15. doi: 10.1186/1750-1172-2-15. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
55. Glenn T.K., Honar H., Liu H., Ter Keurs H.E., Lee S.S. Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. *J. Hepatol.* 2011;55:1249–1255. doi: 10.1016/j.jhep.2011.02.030. [PubMed] [CrossRef] [Google Scholar]
56. Li M.X., Hwang P.M. Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs. *Gene.* 2015;571:153–166. doi: 10.1016/j.gene.2015.07.074. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
57. Kim S.M., George B., Alcivar-Franco D., Campbell C.L., Charnigo R., Delisle B., Hundley J., Darrat Y., Morales G., Elayi S.-C., et al. QT prolongation is associated with increased mortality in end stage liver disease. *World J. Cardiol.* 2017;9:347–354. doi: 10.4330/wjc.v9.i4.347. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
58. Țieranu E., Donoiu I., Istrătoaie O., Găman A., Țieranu L., Gheonea D., Ciurea T. Q-T Interval Prolongation in Patients with Liver Cirrhosis. *Curr. Health Sci. J.* 2018;44:274–279. [PMC free article] [PubMed] [Google Scholar]
59. Genovesi S., Pizzala D.M.P., Pozzi M., Ratti L., Milanese M., Pieruzzi F.U.E.G., Vincenti A., Stella A., Mancina G., Stramba-Badiale M. QT interval prolongation and decreased heart rate variability in cirrhotic patients: Relevance of hepatic venous pressure gradient and serum calcium. *Clin. Sci.* 2009;116:851–859. doi: 10.1042/CS20080325. [PubMed] [CrossRef] [Google Scholar]
60. Hendrickse M., Triger D. Peripheral and cardiovascular autonomic impairment in chronic liver disease: Prevalence and relation to hepatic function. *J. Hepatol.* 1992;16:177–183. doi: 10.1016/S0168-8278(05)80112-6. [PubMed] [CrossRef] [Google Scholar]
61. Licata A., Novo G., Colomba D., Tuttolomondo A., Galia M., Cammà C. Cardiac involvement in patients with cirrhosis. *J. Cardiovasc. Med.* 2016;17:26–36.

- doi: 10.2459/JCM.0000000000000288. [PubMed] [CrossRef] [Google Scholar]
62. Wiese S., Mortensen C., Gøtze J.P., Christensen E., Andersen O., Bendtsen F., Møller S. Cardiac and proinflammatory markers predict prognosis in cirrhosis. *Liver Int.* 2014;34:e19–e30. doi: 10.1111/liv.12428. [PubMed] [CrossRef] [Google Scholar]
63. Møller S., Danielsen K.V., Wiese S., Hove J., Bendtsen F. An update on cirrhotic cardiomyopathy. *Expert Rev. Gastroenterol. Hepatol.* 2019;13:497–505. doi: 10.1080/17474124.2019.1587293. [PubMed] [CrossRef] [Google Scholar]
64. Liu H., Jayakumar S., Traboulsi M., Lee S.S. Cirrhotic cardiomyopathy: Implications for liver transplantation. *Liver Transplant.* 2017;23:826–835. doi: 10.1002/lt.24768. [PubMed] [CrossRef] [Google Scholar]
65. Schnell F., Donal E., Lorho R., Lavoué S., Gacouin A., Compagnon P., Boudjema K., Mabo P., Le Tulzo Y., Camus C. Severe left-sided heart failure early after liver transplantation. *Liver Transplant.* 2009;15:1296–1305. doi: 10.1002/lt.21822. [PubMed] [CrossRef] [Google Scholar]
66. Dote K., Sato H., Tateishi H., Uchida T., Ishihara M. [Myocardial stunning due to simultaneous multivessel coronary spasms: A review of 5 cases] *J. Cardiol.* 1991;21:203–214. [PubMed] [Google Scholar]
67. Saner F.H., Plicht B., Treckmann J., Máthé Z., Sotiropoulos G.C., Radtke A., Beckebaum S., Cicinnati V., Paul A. Tako-Tsubo syndrome as a rare cause of cardiac failure in liver transplantation. *Liver Int.* 2010;30:159–160. doi: 10.1111/j.1478-3231.2009.02062.x. [PubMed] [CrossRef] [Google Scholar]
68. Bainbridge D., Cheng D. Stress-induced cardiomyopathy in the perioperative setting. *Can. J. Anesth.* 2009;56:397–401. doi: 10.1007/s12630-009-9085-y. [PubMed] [CrossRef] [Google Scholar]
69. Pilgrim T., Wyss T. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: A systematic review. *Int. J. Cardiol.* 2008;124:283–292. doi: 10.1016/j.ijcard.2007.07.002. [PubMed] [CrossRef] [Google Scholar]
70. Tomescu D.R., Tulbure D., Dima S., Ungureanu D., Popescu M., Popescu I. First Report of Cytokine Removal using CytoSorb® in Severe Noninfectious Inflammatory Syndrome after Liver Transplantation. *Int. J. Artif. Organs.* 2016;39:136–140. doi: 10.5301/ijao.5000489. [PubMed] [CrossRef] [Google Scholar]
71. Sato H., Tateishi H., Uchida T. Takotsubo-type cardiomyopathy due to multivessel spasm. In: Kodama K., Haze K., Hon M., editors. *Clinical Aspect of Myocardial Injury: From Ischemia to Heart Failure*. Kagakuhyoronsha; Tokyo, Japan: 1990. pp. 56–64. [Google Scholar]

72. Nakano T., Onoue K., Nakada Y., Nakagawa H., Kumazawa T., Ueda T., Nishida T., Soeda T., Okayama S., Watanabe M., et al. Alteration of β -Adrenoceptor Signaling in Left Ventricle of Acute Phase Takotsubo Syndrome: A Human Study. *Sci. Rep.* 2018;8:12731. doi: 10.1038/s41598-018-31034-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
73. Sandhu G., Servetnyk Z., Croitor S., Herzog E. Atropine aggravates signs and symptoms of Takotsubo cardiomyopathy. *Am. J. Emerg. Med.* 2010;28:258.e5–258.e7. doi: 10.1016/j.ajem.2009.06.011. [PubMed] [CrossRef] [Google Scholar]
74. Fouad T.R., Abdel-Razek W., Burak K.W., Bain V.G., Lee S.S. Prediction of Cardiac Complications After Liver Transplantation. *Transplantation.* 2009;87:763–770. doi: 10.1097/TP.0b013e318198d734. [PubMed] [CrossRef] [Google Scholar]
75. Josefsson A., Fu M., Allayhari P., Björnsson E.S., Castedal M., Olausson M., Kalaitzakis E. Impact of peri-transplant heart failure & left-ventricular diastolic dysfunction on outcomes following liver transplantation. *Liver Int.* 2012;32:1262–1269. [PubMed] [Google Scholar]
76. Sonny A., Ibrahim A., Schuster A., Jaber W.A., Cywinski J.B. Impact and persistence of cirrhotic cardiomyopathy after liver transplantation. *Clin. Transplant.* 2016;30:986–993. doi: 10.1111/ctr.12778. [PubMed] [CrossRef] [Google Scholar]
77. Qureshi W., Mittal C., Ahmad U., Alirhayim Z., Hassan S., Qureshi S., Khalid F. Clinical predictors of post-liver transplant new-onset heart failure. *Liver Transplant.* 2013;19:701–710. doi: 10.1002/lt.23654. [PubMed] [CrossRef] [Google Scholar]
78. Albeldawi M., Aggarwal A., Madhwal S., Cywinski J., Lopez R., Egtesad B., Zein N.N. Cumulative risk of cardiovascular events after orthotopic liver transplantation. *Liver Transplant.* 2012;18:370–375. doi: 10.1002/lt.22468. [PubMed] [CrossRef] [Google Scholar]
79. Ikegami T., Shirabe K., Soejima Y., Taketomi A., Yoshizumi T., Uchiyama H., Harada N., Maehara Y. The impact of renal replacement therapy before or after living donor liver transplantation. *Clin. Transplant.* 2011;26:143–148. doi: 10.1111/j.1399-0012.2011.01450.x. [PubMed] [CrossRef] [Google Scholar]
80. Sehgal L., Srivastava P., Pandey C.K., Jha A. Preoperative cardiovascular investigations in liver transplant candidate: An update. *Indian J. Anaesth.* 2016;60:12–18. doi: 10.4103/0019-5049.174870. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
81. Sattar Y., Siew K.S.W., Connerney M., Ullah W., Alraies M.C. Management of Takotsubo Syndrome: A Comprehensive Review. *Cureus.* 2020;12:e6556.

- doi: 10.7759/cureus.6556. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
82. Petäjä E.M., Yki-Järvinen H. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review. *Int. J. Mol. Sci.* 2016;17:633. doi: 10.3390/ijms17050633. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
83. Kanwar P., Kowdley K.V. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. *Clin. Liver Dis.* 2016;20:225–243. doi: 10.1016/j.cld.2015.10.002. [PubMed] [CrossRef] [Google Scholar]
84. Ipsen D.H., Lykkesfeldt J., Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. *Cell. Mol. Life Sci.* 2018;75:3313–3327. doi: 10.1007/s00018-018-2860-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
85. Ekstedt M., Hagström H., Nasr P., Fredrikson M., Stal P., Kechagias S., Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. *Hepatology.* 2015;61:1547–1554. doi: 10.1002/hep.27368. [PubMed] [CrossRef] [Google Scholar]
86. Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Björnsson E.S., Charatcharoenwitthaya P., Mills P.R., Keach J.C., Lafferty H.D., Stahler A., et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology.* 2015;149:389–397.e10. doi: 10.1053/j.gastro.2015.04.043. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
87. Motamed N., Rabiee B., Poustchi H., Dehestani B., Hemmasi G.R., Khansari M., Maadi M., Saeedian F.S., Zamani F. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. *Clin. Res. Hepatol. Gastroenterol.* 2017;41:31–38. doi: 10.1016/j.clinre.2016.07.005. [PubMed] [CrossRef] [Google Scholar]
88. Haddad T.M., Hamdeh S., Kanmanthareddy A., Alla V.M. Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. *Diabetes Metab. Syndr. Clin. Res. Rev.* 2017;11:S209–S216. doi: 10.1016/j.dsx.2016.12.033. [PubMed] [CrossRef] [Google Scholar]
89. Assy N.N., Djibre A., Farah R., Grosovski M., Marmor A. Presence of Coronary Plaques in Patients with Nonalcoholic Fatty Liver Disease 1. *Radiology.* 2010;254:393–400. doi: 10.1148/radiol.09090769. [PubMed] [CrossRef] [Google Scholar]

90. Pinarbasi B., Demir K., Oflaz H., Ahishali E., Akyuz F., Elitok A., Cimen A.O., Golcuk E., Gulluoglu M., Issever H., et al. Measurement of the coronary flow velocity reserve in patients with non-alcoholic fatty liver disease. *Turk. J. Gastroenterol.* 2012;23:720–726. doi: 10.4318/tjg.2012.0489. [PubMed] [CrossRef] [Google Scholar]
91. Wan S.-H., Vogel M.W., Chen H.H. Pre-clinical diastolic dysfunction. *J. Am. Coll. Cardiol.* 2013;63:407–416. doi: 10.1016/j.jacc.2013.10.063. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
92. Mantovani A., Zoppini G., Targher G., Golia G., Bonora E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. *J. Endocrinol. Investig.* 2012;35:215–218. doi: 10.1007/BF03345421. [PubMed] [CrossRef] [Google Scholar]
93. Markus M.R.P., Baumeister S.E., Stritzke J., Dörr M., Wallaschofski H., Völzke H., Lieb W. Hepatic Steatosis Is Associated With Aortic Valve Sclerosis in the General Population. *Arter. Thromb. Vasc. Boil.* 2013;33:1690–1695. doi: 10.1161/ATVBAHA.112.300556. [PubMed] [CrossRef] [Google Scholar]
94. Mantovani A., Pernigo M., Bergamini C., Bonapace S., Lipari P., Valbusa F., Bertolini L., Zenari L., Pichiri I., Dauriz M., et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Metabolism.* 2015;64:879–887. doi: 10.1016/j.metabol.2015.04.003. [PubMed] [CrossRef] [Google Scholar]
95. Mantovani A. Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis. *J. Clin. Transl. Hepatol.* 2017;5:134–141. doi: 10.14218/JCTH.2017.00005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
96. Tana C., Ballestri S., Ricci F., Di Vincenzo A., Ticinesi A., Gallina S., Giamberardino M.A., Cipollone F., Sutton R., Vettor R., et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. *Int. J. Environ. Res. Public Health.* 2019;16:3104. doi: 10.3390/ijerph16173104. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
97. Fotbolcu H., Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. *World J. Gastroenterol.* 2016;22:4079–4090. doi: 10.3748/wjg.v22.i16.4079. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
98. Gaziano J., Hennekens C.H., O'Donnell C.J., Breslow J.L., Buring J.E. Fasting Triglycerides, High-Density Lipoprotein, and Risk of Myocardial Infarction. *Circulation.* 1997;96:2520–2525. doi: 10.1161/01.CIR.96.8.2520. [PubMed] [CrossRef] [Google Scholar]

99. Niederreiter L., Tilg H. Cytokines and fatty liver diseases. *Liver Res.* 2018;2:14–20. doi: 10.1016/j.livres.2018.03.003. [CrossRef] [Google Scholar]
100. Francque S., Van Der Graaff D., Kwanten W. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. *J. Hepatol.* 2016;65:425–443. doi: 10.1016/j.jhep.2016.04.005. [PubMed] [CrossRef] [Google Scholar]
101. Liu H., Lu H.-Y. Nonalcoholic fatty liver disease and cardiovascular disease. *World J. Gastroenterol.* 2014;20:8407–8415. doi: 10.3748/wjg.v20.i26.8407. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
102. Adolph T.E., Grander C., Grabherr F., Tilg H. Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. *Int. J. Mol. Sci.* 2017;18:1649. doi: 10.3390/ijms18081649. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
103. Tariq Z., Green C.J., Hodson L. Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? *Liver Int.* 2014;34:e180–e190. doi: 10.1111/liv.12523. [PubMed] [CrossRef] [Google Scholar]
104. Polimeni L., Del Ben M., Baratta F., Perri L., Albanese F., Pastori D., Violi F., Angelico F. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. *World J. Hepatol.* 2015;7:1325–1336. doi: 10.4254/wjh.v7.i10.1325. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
105. Semenkovich C.F. Insulin resistance and atherosclerosis. *J. Clin. Investig.* 2006;116:1813–1822. doi: 10.1172/JCI29024. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
106. Kotronen A., Joutsu-Korhonen L., Sevastianova K., Bergholm R., Hakkarainen A., Pietiläinen K.H., Lundbom N., Rissanen A., Lassila R., Yki-Järvinen H. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. *Liver Int.* 2010;31:176–183. doi: 10.1111/j.1478-3231.2010.02375.x. [PubMed] [CrossRef] [Google Scholar]
107. Loeffen R., Spronk H., Cate H.T. The impact of blood coagulability on atherosclerosis and cardiovascular disease. *J. Thromb. Haemost.* 2012;10:1207–1216. doi: 10.1111/j.1538-7836.2012.04782.x. [PubMed] [CrossRef] [Google Scholar]
108. Verrijken A., Francque S., Mertens I., Prawitt J., Caron S., Hubens G., Van Marck E., Staels B., Michielsen P., Van Gaal L. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Hepatology.* 2013;59:121–129.

- doi: 10.1002/hep.26510. [PubMed] [CrossRef] [Google Scholar]
109. Tofler G.H., Massaro J., O'Donnell C., Wilson P., Vasan R., Sutherland P., Meigs J., Levy D., D'Agostino R. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study. *Thromb. Res.* 2016;140:30–35. doi: 10.1016/j.thromres.2016.02.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
110. Barb D., Bril F., Kalavalapalli S., Cusi K. Plasma Fibroblast Growth Factor 21 Is Associated with Severity of Nonalcoholic Steatohepatitis in Patients with Obesity and Type 2 Diabetes. *J. Clin. Endocrinol. Metab.* 2019;104:3327–3336. doi: 10.1210/jc.2018-02414. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
111. Chow W., Xu A., Woo Y.C., Tso A.W., Cheung S.C., Fong C.H., Tse H.-F., Chau M.T., Cheung B.M.Y., Lam K.S.L. Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors. *Arter. Thromb. Vasc. Boil.* 2013;33:2454–2459. doi: 10.1161/ATVBAHA.113.301599. [PubMed] [CrossRef] [Google Scholar]
112. Shen Y., Ma X., Zhou J., Pan X., Hao Y., Zhou M., Lu Z., Gao M., Bao Y., Jia W. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. *Cardiovasc. Diabetol.* 2013;12:124. doi: 10.1186/1475-2840-12-124. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
113. Haukeland J.W., Dahl T.B., Yndestad A., Gladhaug I.P., Løberg E.M., Haaland T., Konopski Z., Wium C., Aasheim E.T., Johansen O.E., et al. Fetuin A in nonalcoholic fatty liver disease: In vivo and in vitro studies. *Eur. J. Endocrinol.* 2012;166:503–510. doi: 10.1530/EJE-11-0864. [PubMed] [CrossRef] [Google Scholar]
114. Weikert C., Stefan N., Schulze M.B., Pischon T., Berger K., Joost H.-G., Häring H.-U., Boeing H., Fritsche A. Plasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke. *Circulation.* 2008;118:2555–2562. doi: 10.1161/CIRCULATIONAHA.108.814418. [PubMed] [CrossRef] [Google Scholar]
115. Wong V.W.-S., Adams L.A., De Lédinghen V., Wong G.L.-H., Sookoian S. Noninvasive biomarkers in NAFLD and NASH—Current progress and future promise. *Nat. Rev. Gastroenterol. Hepatol.* 2018;15:461–478. doi: 10.1038/s41575-018-0014-9. [PubMed] [CrossRef] [Google Scholar]
116. Simon T.G., Corey K.E., Cannon C.P., Blazing M., Park J.-G., O'Donoghue M.L., Chung R.T., Giugliano R.P. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. *Int. J. Cardiol.* 2018;270:245–252.

- doi: 10.1016/j.ijcard.2018.05.087. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
117. El Hadi H., Di Vincenzo A., Vettor R., Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. *Int. J. Mol. Sci.* 2019;20:2215. doi: 10.3390/ijms20092215. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
118. Ogawa T., De Bold A.J. The heart as an endocrine organ. *Endocr. Connect.* 2014;3:R31–R44. doi: 10.1530/EC-14-0012. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
119. Wu Y.-S., Zhu B., Luo A.-L., Yang L., Yang C. The Role of Cardiokines in Heart Diseases: Beneficial or Detrimental? *BioMed Res. Int.* 2018;2018:1–14. doi: 10.1155/2018/8207058. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
120. Shimano M., Ouchi N., Walsh K. Cardiokines: Recent progress in elucidating the cardiac secretome. *Circulation.* 2012;126:e327–e332. doi: 10.1161/CIRCULATIONAHA.112.150656. [PubMed] [CrossRef] [Google Scholar]
121. Rashed H.M., Nair B.G., Patel T.B. Regulation of hepatic glycolysis and gluconeogenesis by atrial natriuretic peptide. *Arch. Biochem. Biophys.* 1992;298:640–645. doi: 10.1016/0003-9861(92)90460-E. [PubMed] [CrossRef] [Google Scholar]
122. Jahng J.W.S., Song E., Sweeney G. Crosstalk between the heart and peripheral organs in heart failure. *Exp. Mol. Med.* 2016;48:e217. doi: 10.1038/emm.2016.20. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
123. Kato T., Niizuma S., Inuzuka Y., Kawashima T., Okuda J., Kawamoto A., Tamaki Y., Iwanaga Y., Soga T., Kita T., et al. Analysis of liver metabolism in a rat model of heart failure. *Int. J. Cardiol.* 2012;161:130–136. doi: 10.1016/j.ijcard.2011.07.056. [PubMed] [CrossRef] [Google Scholar]
124. Grueter C.E., Van Rooij E., Johnson B.A., DeLeon S., Sutherland L.B., Qi X., Gautron L., Elmquist J.K., Bassel-Duby R., Olson E.N. A Cardiac MicroRNA Governs Systemic Energy Homeostasis by Regulation of MED13. *Cell.* 2012;149:671–683. doi: 10.1016/j.cell.2012.03.029. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
125. Baskin K.K., E Grueter C., Kusminski C.M., Holland W.L., Bookout A.L., Satapati S., Kong Y.M., Burgess S.C., Malloy C.R., E Scherer P., et al. MED 13-dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver. *EMBO Mol. Med.* 2014;6:1610–1621. doi: 10.15252/emmm.201404218. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

126. Nakamura M., Sadoshima J. Heart over mind: Metabolic control of white adipose tissue and liver. *EMBO Mol. Med.* 2014;6:1521–1524. doi: 10.15252/emmm.201404749. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
127. Alter P., Glück T., Figiel J.H., Koczulla A.R., Vogelmeier C.F., Rupp H., Information P.E.K.F.C. From Heart Failure to Highly Unsaturated Fatty Acid Deficiency and Vice Versa: Bidirectional Heart and Liver Interactions. *Can. J. Cardiol.* 2016;32:217–225. doi: 10.1016/j.cjca.2015.05.019. [PubMed] [CrossRef] [Google Scholar]
128. Jobe L.J., Meléndez G.C., Levick S.P., Du Y., Brower G.L., Janicki J.S. TNF-alpha inhibition attenuates adverse myocardial remodeling in a rat model of volume overload. *Am. J. Physiol. Circ. Physiol.* 2009;297:H1462–H1468. doi: 10.1152/ajpheart.00442.2009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
129. Cagli, K.; Ba,sar, F.N.; Tok, D.; Turak, O.; Ba,sar, Ö.; Ça ˘gli, K. How to interpret liver function tests in heart failure patients? *Turk. J. Gastroenterol.* 2020, 26, 197–203. [CrossRef] [PubMed]
130. Hilscher, M.; Sanchez, W. Congestive hepatopathy. *Clin. Liver Dis.* 2016, 8, 68–71. [CrossRef] [PubMed]
131. Fouad, Y.M.; Yehia, R. Hepato-cardiac disorders. *World J. Hepatol.* 2014, 6, 41–54. [CrossRef] [PubMed]
132. Alvarez, A.M.; Mukherjee, D. Liver Abnormalities in Cardiac Diseases and Heart Failure. *Int. J. Angiol.* 2011, 20, 135–142. [CrossRef]
133. Lautt, W.W.; Greenway, C.V. Conceptual review of the hepatic vascular bed. *Hepatology* 1987, 7, 952–963. [CrossRef] [PubMed]
134. Lautt, W.W. Hepatic circulation: Physiology and pathophysiology. In *Colloquium Series on Integrated Systems Physiology: From Molecule to Function*; Morgan & Claypool Publishers: California, CA, USA, 2009; Volume 1, pp. 1–174.
135. Kiernan, F. XXIX. The anatomy and physiology of the liver. *Philos. Trans. R. Soc. Lond.* 1833, 123, 711–770. [CrossRef]
136. Sherlock, S. The Liver in Heart Failure Relation of Anatomical, Functional, and Circulatory Changes. *Heart* 1951, 13, 273–293. [CrossRef] [PubMed]
137. Weisberg, I.S.; Jacobson, I.M. Cardiovascular Diseases and the Liver. *Clin. Liver Dis.* 2011, 15, 1–20. [CrossRef]
138. Asrani, S.; Asrani, N.S.; Freese, D.K.; Phillips, S.D.; Warnes, C.A.; Heimbach, J.; Kamath, P.S. Congenital heart disease and the liver. *Hepatology* 2012, 56, 1160–1169. [CrossRef]
139. Naschitz, J.E.; Slobodin, G.; Lewis, R.J.; Zuckerman, E.; Yeshurun, D. Heart diseases affecting the liver and liver diseases affecting the heart. *Am. Hear.*

- J. 2000, 140, 111–120. [CrossRef]
140. Samsky, M.D.; Patel, C.B.; DeWald, T.A.; Smith, A.D.; Felker, G.M.; Rogers, J.G.; Hernandez, A.F. Cardiohepatic interactions in heart failure: An overview and clinical implications. *J. Am. Coll. Cardiol.* 2013, 61, 2397–2405. [CrossRef]
141. Gao, M.; Cheng, Y.; Zheng, Y.; Zhang, W.; Wang, L.; Qin, L. Association of serum transaminases with short-and long-term out-comes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. *BMC Cardiovasc. Disord.* 2017, 17, 1–8. [CrossRef] [PubMed]
142. Oh, P.C.; Eom, Y.S.; Moon, J.; Jang, H.-J.; Kim, T.-H.; Suh, J.; Kong, M.G.; Park, S.-D.; Kwon, S.W.; Choe, J.Y.; et al. Prognostic impact of the combination of serum transaminase and alkaline phosphatase determined in the emergency room in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *PLoS ONE* 2020, 15, e0233286. [CrossRef] [PubMed]
143. Moon, J.; Kang, W.; Oh, P.C.; Seo, S.Y.; Lee, K.; Han, S.H.; Ahn, T.; Shin, E. Serum transaminase determined in the emergency room predicts outcomes in patients with acute ST-segment elevation myocardial infarction who undergo primary percutaneous coronary intervention. *Int. J. Cardiol.* 2014, 177, 442–447. [CrossRef]
144. Huseynov, A.; Baumann, S.; Becher, T.; Koepp, J.; Lang, S.; Jabbour, C.; Behnes, M.; Borggreffe, M.; Akin, I. Liver and cholestatic pa-rameters as prognostic biomarkers of in-hospital MACE in patients with STEMI. *Eur. J. Clin. Investig.* 2016, 46, 721–729. [CrossRef]
145. Kim, J.G.; Chang, K.; Choo, E.H.; Lee, J.-M.; Seung, K.-B. Serum gamma-glutamyl transferase is a predictor of mortality in patients with acute myocardial infarction. *Medicine* 2018, 97, e11393. [CrossRef]
146. Nikolaou, M.; Parissis, J.; Yilmaz, M.B.; Seronde, M.-F.; Kivikko, M.; Laribi, S.; Paugam-Burtz, C.; Cai, D.; Pohjanjousi, P.; Laterre, P.-F.; et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. *Eur. Heart J.* 2013, 34, 742–749. [CrossRef]
147. Poelzl, G.; Ess, M.; Von der Heide, A.; Rudnicki, M.; Frick, M.; Ulmer, H. Concomitant renal and hepatic dysfunctions in chronic heart failure: Clinical implications and prognostic significance. *Eur. J. Intern. Med.* 2013, 24, 177–182. [CrossRef] [PubMed]
148. Møller, S.; Henriksen, J.H. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. *Heart* 2002, 87, 9–15. [CrossRef]
149. Møller, S.; Bendtsen, F. The pathophysiology of arterial vasodilatation and

- hyperdynamic circulation in cirrhosis. *Liver Int.* 2018, 38, 570–580. [CrossRef]
150. Sampaio, F.; Pimenta, J.; Bettencourt, N.; Fontes-Carvalho, R.; Silva, A.P.; Valente, J.; Bettencourt, P.; Fraga, J.; Gama, V. Systolic and diastolic dysfunction in cirrhosis: A tissue-Doppler and speckle tracking echocardiography study. *Liver Int.* 2013, 33, 1158–1165. [CrossRef] [PubMed]
151. Ruíz-Del-Árbol, L.; Achécar, L.; Serradilla, R.; Rodríguez-Gandía, M.Á.; Rivero, M.; Garrido, E.; Natcher, J.J. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. *Hepatology* 2013, 58, 1732–1741. [CrossRef]
152. Parekh, N.K.; Hynan, L.S.; De Lemos, J.; Lee, W.M.; Acute Liver Failure Study Group. Elevated troponin I levels in acute liver failure: Is myocardial injury an integral part of acute liver failure? *Hepatology* 2007, 45, 1489–1495. [CrossRef]
153. Wu, T.T.; Yuan, A.; Chen, C.Y.; Chen, W.J.; Luh, K.T.; Kuo, S.H.; Lin, F.Y.; Yang, P.C. Cardiac troponin I levels are a risk factor for mortality and multiple organ failure in noncardiac critically ill patients and have an additive effect to the APACHE II score in outcome prediction. *Shock* 2004, 22, 95–101. [CrossRef]
154. Lofthus, D.M.; Stevens, S.R.; Armstrong, P.W.; Granger, C.B.; Mahaffey, K.W. Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. *Coron. Artery Dis.* 2012, 23, 22–30. [CrossRef] [PubMed]
155. Lazzeri, C.; Valente, S.; Boddi, M.; Mecarocci, V.; Chiostrì, M.; Gensini, G.F. Clinical and prognostic significance of increased liver enzymes in ST-elevation myocardial infarction. *Int. J. Cardiol.* 2014, 177, 543–544. [CrossRef] [PubMed]

Chapter: 8

Arabic Abstract

ملخص عربي

المتلازمة القلبية الكبدية بين مرضى قصور القلب في اليمن

أهداف الدراسة: هدفت الدراسة الحالية للتحقق في الحالات السريرية للمتلازمة القلبية الكبدية بين مرضى قصور القلب المتواجدين في العديد من المستشفيات الخاصة والعامة في مدينة صنعاء ، اليمن.

الطريقة: كانت الدراسة عبارة عن دراسة سريرية مقطعية أجريت على مرضى قصور القلب الذي تم إدخالهم إلى الأقسام الطبية في العديد من المستشفيات الخاصة والعامة في مدينة صنعاء بين 1 يوليو 2021 و 31 ديسمبر 2021.

النتائج: تمت دراسة مجموعه 162 حالة مرضية تم تشخيصها من المتلازمة القلبية الكبدية. بلغ عدد المرضى الذكور 117 (72.2%) والمرضى الإناث 45 (27.8%). تراوحت أعمار مرضى المتلازمة القلبية الكبدية بين 0.5 و 81 سنة. أظهرت نتائج الدراسة الحالية أن معظم مرضى المتلازمة القلبية الكبدية تتراوح أعمارهم بين 41 و 70 سنة (66.1%). تم إدخال معظم مرضى المتلازمة القلبية الكبدية إلى مستشفى لبنان (75.3%) يليه مستشفى الثورة (10.5%). المرضى الذين يعانون من المتلازمة القلبية الكبدية غالبًا ما يصابون بالوذمة (56.2%) والشحوب (40.7%) والزرقة (25.3%). وكانت الأعراض الأخرى الأقل تكرارًا هي اليرقان (8.6%) والهاورات (8%). كان متوسط معدلات النبض لدى مرضى المتلازمة القلبية الكبدية 94 ضربة في الدقيقة (بحد أقصى 142 و حد أدنى 37) ، وكان متوسط ضغط الدم الانقباضي 118 ملم زئبقي (بحد أقصى 200 و كحد أدنى 60) ، وكان متوسط ضغط الدم الانبساطي 75 ملم زئبقي (حد أقصى 120 وحد أدنى 40) . تضمنت الفحوصات المختبرية التي تم إجراؤها للمرضى لتقييم وظائف الكبد ، البيليروبين الكلي ، والبيليروبين المباشر ، والبيليروبين غير المباشر ، وانزيمات الكبد AST ، و ALT ، و ALP ، والبروتين الكلي ، والألبومين ، ووقت البروثرومين ، ووقت الثرومبوبلاستين الجزئي المنشط. بالإضافة إلى ذلك تم إجراء تعداد الدم الكامل الروتيني واختبارات وظائف الكلى. فوجدنا أن نسبة كبيرة من المرضى (55.7%) يعانون من قصور في القلب مع الكسر القذفي المحفوظ (HFpEF) بينما كان 28.2% من المرضى الذين يعانون من قصور في القلب مع انخفاض الكسر القذفي (HFrEF). وكانت أقلية بنسبة (9.9%) من المرضى قصور في القلب مع كسر طرد متوسط المدى (HFmrEF) وكانت نسبة 6.1% من المرضى عندهم كسر طرد طبيعي.

الاستنتاجات: تظهر المتلازمة القلبية الكبدية مع مجموعة كاملة من العلامات والأعراض اختلافات الفحوصات المخبرية ، وهي أكثر انتشارًا في مرضى قصور القلب من الذكور في منتصف العمر وتزداد احتمالية الإصابة بالمتلازمة القلبية الكبدية أيضًا في المرضى الذين يعانون من انخفاض الكسر القذفي.



الجمهورية اليمنية
وزارة التعليم العالي والبحث العلمي
جامعة 21 سبتمبر للعلوم الطبية
كلية الصيدلة السريرية

المتلازمة القلبية الكبدية بين مرضى قصور القلب في اليمن

بحث تخرج مقدم كمتهم جزئي للحصول على درجة البكالوريوس في الصيدلة

مقدم من الطلاب:

غادة عادل بادي
اصالة عبدالحليم خاوز
نور علي العززي
سارة عبدالعزيز البكير
عبير محمد مهدي
لمياء محمود مدهيش

احمد إبراهيم الخولي
اصيل عبد الجبار ريشان
إبراهيم عبدالله باكر
اسامه حسن القعيش
اصيل عبدالحليم خاوز
هيثم حامس قاسم
طارق علي السياغي

تحت اشراف:

د/ شوقي حسين ناجي العودي
أستاذ مساعد علم الأدوية والصيدلة السريرية
كلية الطب - جامعة ذمار

د/ مختار عبدالحافظ الغرافي
أستاذ مشارك الكيمياء الدوائية والعضوية الصيدلانية
كلية الصيدلة - جامعة صنعاء

2022-2021

